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Abstract 
Pyranose-Furanose mutases are enzymes that catalyze the isomerization of six-membered 
pyranose and five-membered furanose forms of a nucleotide-based sugar. In this research, the 
substrate binding site of three different mutases were investigated; UDP-galactopyranose mutase 
(UGM), GDP-altro-heptopyranose mutase (GaHM) and UDP-arabinopyranose mutase (UAM). 
Both UGM and UAM use a UDP-based sugar as the substrate but require different cofactors, flavin 
adenine dinucleotide (FAD) and Mn2+ respectively, to function. UGM and GaHM use the same 
cofactor (FAD), but the latter prefers to work with a GDP-based sugar. In this thesis, studies have 
been conducted on these three mutases using a variety of tools, such as X-ray crystallography, 
protein modeling, site-directed mutagenesis and kinetic assays, to understand how these enzymes 
bind their respective substrates.  
Among these three mutases, UGM is the best-studied enzyme and is a validated drug target 
in Mycobacteria.  Despite this, the structural role of some active site residues in substrate binding 
is not clearly understood. Deinococcus radiodurans UGM (DrUGM) mutants of active site 
residues Trp184, Arg364, His88, and Asn372 were prepared and evaluated using kinetic and 
docking studies. The results suggested that these residues are vital to the positioning of UDP-
galactopyranose under FAD in a productive conformation, for maximum enzyme efficiency. 
Inhibition studies, using the inhibitor MS-208, were performed on Mycobacterium tuberculosis 
UGM (MtUGM). Kinetic assays indicated that MS-208 is a mixed-type inhibitor of MtUGM.  
In this study, the crystal structures of Campylobacter jejuni GaHM (CjGaHM) with a 
substrate mimic GDP-mannose were solved, allowing for a comparison of GaHM and UGM 
substrate binding sites. The results highlighted the alterations undergone by CjGaHM to 
accommodate a GDP-based substrate in the active site.  
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A preliminary model of UAM was built based on the protein sequence of Oryza sativa 
UAM1 (OsUAM1) using the protein structure modeling servers I-TASSER and GalaxyWEB. The 
models suggested that, unlike the catalytic role played by the FAD cofactor in UGM and GaHM, 
the role of the Mn2+ cofactor in UAM could be to aid the stabilization of the negative charge of the 
substrate diphosphate. Furthermore, experiments with mutants of OsUAM1 have helped identify 
residues that may bind the metal cofactor. 
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Chapter 1: Introduction 
1.1 Importance of furanoses in cell walls of organisms 
Bacteria, fungi, protozoa, and plants have an outer cell wall that protects the vulnerable 
contents of the cell. Repeating units of carbohydrates, commonly referred to as polysaccharides, 
form one of the major components of the cell wall. Understanding the various polysaccharides that 
constitute the cell wall of these organisms, explaining the formation and necessity of these complex 
polysaccharides and decoding the function of the enzymes that aid in their biosynthesis represents 
an attractive avenue for research. The monosaccharide sugar units that make up these 
polysaccharides can exist either as six-membered pyranose sugars or five-membered furanose 
sugars. Although the pyranose form is more abundant of the two, the furanose form is no less 
important.  
Furanoses have been identified in the cell wall of bacteria, fungi, protozoa, and plants.1 
Gram-negative bacteria have an outer membrane called the lipopolysaccharide (LPS) layer that 
lies outside the thin peptidoglycan layer. The LPS layer has O-antigens or O-polysaccharides 
consisting of sugars in the furanose ring form. For example, D-galactofuranose (D-Galf), arguably 
the most abundant furanose-sugar, has been identified in O-antigens of bacteria such as 
Escherichia coli (E. coli), Klebsiella pneumonia (K. pneumoniae), Shigella dysenteriae (S. 
dysenteriae) and Salmonella typhimurium (S. typhimurium).2-4 Other furanose sugars are also 
incorporated in bacterial cell walls. D-arabinofuranose (D-Araf), even though not as common as 
D-Galf, is found in the cell wall glycoconjugates of Actinomycetes, Pseudomonas aeruginosa (P. 
aerugiosa), Azorhizobium caulinodans (A. caulinodans) and in the mycolyl-arabinogalactan layer 
of Mycobacterium sp.5-7 Furanose residues have also been identified in plant cell wall 
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glycoconjugates.8 L-arabinofuranose (L-Araf) residues are found in arabinan and arabinogalactan, 
which are the major structural components of Rhamnogalacturonan I (RGI) in plant pectin.  
Furanoses help to maintain cell wall rigidity. The galactan of Mycobacterium tuberculosis 
(M. tuberculosis), believed to contribute to cell wall structure and impermeability, is a good 
example.9 Furanoses are crucial to cell growth and survival of bacterial, fungal and protozoan 
pathogens. Deletion of the glfA gene, corresponding to an enzyme essential for galactofuranose 
biosynthesis in the fungus Aspergillus fumigatus (A. fumigatus), rendered the cells with a thinner 
galactofuran layer, less virulent and more susceptible to antifungal agents.   
These furanoses are not found in mammalian glycoconjugates.1 Therefore, understanding 
the production and cell wall incorporation of furanoses in organisms pathogenic to humans and 
mammals has its merits. Weakening the cell wall of these harmful organisms has long been 
considered important in controlling their growth and the spread of diseases. Drug molecules 
focused on targeting the furanose biosynthetic pathway represents an option for the development 
of potential chemotherapeutics.10 Although a number of different furanoses have been identified 
and studied in the cell walls of these organisms, only those relevant to this thesis work are 
introduced here. 
 
1.2 D-Galactofuranose 
 D-Galf residues are vital components that are essential for growth and virulence of a 
mycobacteria.9 The galactofuran of the Mycobacterial cell wall, which features numerous long 
chains of D-Galf residues, is a case in point (Figure 1-1).9 These residues were identified in the 
LPS O-antigen polysaccharides of bacteria such as E. coli, K. pneumonia, and S. dysenteriae 
species. They have also been identified in the cell wall architecture of fungi, such as the Aspergillus 
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species and protozoa, such as Leishmania major (L. major).11,12 D-Galf residues have been 
identified in unique glycoconjugates found in pathogenic bacteria and other organisms pathogenic 
to humans and mammals.                                                        
 
Figure 1-1: A representation of D-Galactofuranose identified in Mycobacterium species.1   
D-Galf residues are shown in blue. 
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1.3 Biosynthesis of D-Galactofuranose 
The proposed D-Galf biosynthetic pathway is shown in Figure 1-2.13 Galactopyranose 
(Galp) is phosphorylated to galactose-1-phosphate (G1P) by galactokinase, which adds a 
phosphate group to the C1 of galactose. Then, uridine monophosphate (UMP) is added onto G1P 
by G1P uridylyltransferase to form uridine diphosphate (UDP) galactopyranose (UDP-Galp).14 
Additionally, UDP-Galp can also be synthesized from UDP-glucopyranose (UDP-Glup) by UDP-
galactose-4-epimerase.15 
The enzymes mentioned above constitute the Leloir pathway. UDP-Galf, the precursor of 
D-Galf residues, is formed by the mutase enzyme, UDP-galactopyranose mutase (UGM), which 
interconverts between the six-membered Galp and the five-membered Galf, as shown in Figure 1-
2.2 Finally, galactosyltransferases transfer D-Galf to the cell wall. 
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Figure 1-2: Proposed biosynthesis of D-Galactofuranose through the Leloir pathway.2 
UGM and the UDP-Galf are highlighted.  
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1.4 L-Arabinofuranose  
L-arabinofuranose (L-Araf) is an abundant sugar found in arabinogalactan glycoproteins 
and polysaccharides such as arabinoxylan in hemicelluloses and RG I and II in pectin of plant cell 
wall.8 Arabinan domains, one of the structural components of RGI, have linear chains of (1, 5)-
linked α-L-Araf residues that are substituted by L-Araf at O-2 or O-3, as shown in Figure 1-3.  
 
 
Figure 1-3: A representation of L-arabinofuranose residues in Arabinan of plant 
Rhamnogalacturonan I.3 
L-Araf residues have been highlighted in blue. 
 
 
1.4.1 Biosynthesis of L-Arabinofuranose in plants 
  UDP-arabinopyranose (UDP-Arap) can be formed either by the action of UDP-
xylopyranose 4-epimerase, which catalyzes the epimerization of UDP-xylopyranose to UDP-Arap, 
or by the action of UDP-Arap-1-phosphate pyrophosphorylase, which transfers UMP to L-Arap-
1-phosphate from uridine triphosphate (UTP) (Figure 1-4).16,17 UDP-Arap is then converted to 
UDP-arabinofuranose (UDP-Araf) by the enzyme UDP-arabinopyranose mutase (UAM) (as 
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shown in Figure 1-4).18 Arabinosyltransferases then act on UDP-Araf and transfer L-Araf to the 
plant cell wall. 
 
Figure 1-4: Biosynthesis of L-Arabinofuranose in plants.4 
UAM and UDP-Araf have been highlighted.  
 
 
1.5 6d-D-altro-heptofurnaose  
6-deoxy-D-altro-heptofurnose (6d-D-altro-Hepf) is one of three furanose sugars found in 
the capsular polysaccharide (CPS) and is essential for the virulence of Campylobacter jejuni (C. 
jejuni), a bacterium that causes gastroenteritis in humans.19 The trisaccharide repeat unit of a strain 
of C. jejuni, HS:41 serotype, is comprised of 6d-D-altro-Hepf residues, L-Araf residues and one 
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among either 6-deoxy-L-altrofuranose or D-fucofuranose (D-FucF) occurring as the third furanose 
sugar (shown in Figure 1-5).20 Trisaccharides containing 6d-D-altro-Hepf occur more frequently 
(75%) than those with D-FucF (25%). No information is available with regards to the biosynthetic 
pathway that produces this trisaccharide repeat unit.                                                                         
 
 
 
Figure 1-5: The trisaccharide repeat unit isolated from C. jejuni, HS: 41 serotype.5  
Two different trisaccharide repeat units having both 6-deoxy-D-altro-Hepf (in blue) and 
L-arabinofuranose have been shown. The difference between these trisaccharide repeat units is 
the presence of either D-fucofuranose or 6-deoxy-L-altrofuranose. 
 
1.6 Precursors of furanoses 
 The common theme emerging from the biosynthetic pathways described above is the 
requirement of sugar nucleotides for the formation and incorporation of furanose sugars in the cell 
wall. Nucleoside diphosphate sugars act as precursors of the furanoses. In other words, the 
activated furanose sugar donors are essential for the formation of furanose residues. UDP-D-Galf 
is thus the precursor of Galf residues.21 Similarly, UDP-L-Araf and GDP-6d-D-altro-Hepf are the 
precursors of L-Araf and 6d-D-altro-Hepf, respectively. 
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1.7 Pyranose-furanose mutases 
Another theme observed in these pathways is the presence of a pyranose-furanose mutase 
enzyme which catalyzes the production of the precursors described above. These mutases are 
named based on the nucleotide-sugar they act on. For example, in the illustration shown for the 
biosynthesis of D-Galf (Figure 1-3), the mutase that works on interconverting the six and five-
membered galactose rings using UDP as the nucleotide is named UDP-galactopyranose mutase 
(UGM). Pyranose-furanose mutases which are the focus of this thesis will be introduced in this 
chapter. Apart from UGM, UAM, and GDP-altroheptopyranose mutase (GaHM) will be 
discussed. 
 
1.7.1 UDP-galactopyranose mutase  
The glf gene encoding for UGM was first identified in E.coli.2 Subsequently, the gene has 
been identified in K. pneumoniae, M. tuberculosis, and many other pathogenic bacteria, fungi, and 
protozoan parasites.22 UGM is a flavin adenine dinucleotide (FAD) containing enzyme that 
interconverts between UDP-Galp (six-membered ring) and UDP-Galf (five-membered ring). The 
equilibrium of this ring contraction reaction favors the six-membered pyranose ring formation in 
a ratio of 9:1. The reaction scheme is shown below (Figure 1-6). 
     
  
Figure 1-6: Reaction catalyzed by UGM.6  
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FAD is non-covalently bound to the enzyme.23 The purified UGM fractions were yellow 
in color and peaks corresponding to the presence of flavin were observed in UV-visible spectra at 
A382 and A450. To provide further evidence for the presence of the FAD cofactor, UGM fractions 
were thermally denatured, and the peaks corresponding to FAD were observed when analyzed on 
HPLC.2 Later, crystal structures were solved to study the binding and interaction of the FAD 
cofactor with UGM. In general, the molecular weight of UGM was determined to be in the 43 - 45 
kDa range. The molecular weight of E. coli UGM (EcUGM) determined by mass spectrometric 
analysis was 43 kDa, and that of K. pneumoniae UGM (KpUGM) was ~ 45 kDa. Gel filtration 
techniques revealed that KpUGM exists as a dimer.3 The bacterial UGMs identified thus far exist 
as a homodimer except Deinococcus radiodurans (D. radiodurans) UGM (DrUGM), which is 
believed to exist and function as a decamer.24  
Gene knock-out experiments have demonstrated that the loss of the glf1 gene rendered 
Mycobacterium smegmatis (M. smegmatis) cells incapable of growth.9 Significant interest was 
generated in studying this mutase and its mechanism, due to its important role in bacterial survival. 
Moreover, the absence of both D-Galf residues and UGM in humans and mammals means that 
UGM is a potential drug target.  
 
1.7.2 Mechanism of UDP-galactopyranose mutase 
 Considerable effort has been dedicated to investigating the mechanism of action of UGM. 
This unique ring contraction reaction is proposed to proceed through the formation of an iminium 
ion intermediate formed via an SN2 reaction (Figure 1-7).
25 It was already known from positional 
isotope exchange (PIX) experiments that the bond between the C1 anomeric carbon of Galp and 
UDP breaks and reforms during the reaction (Figure 1-7). Additionally, the flavin had to be 
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reduced for the reaction to occur, as the enzyme remained inactive under oxidizing conditions.23 
Evidence for the formation of the iminium intermediate was obtained by trapping the FAD-
galactose adduct using sodium cyanoborohydride and radiolabeled UDP-Galp.25 Once the iminium 
ion intermediate is formed, the reaction proceeds by ring closure to form the five-membered 
furanose and attack of UDP to form UDP-Galf, as shown in Figure 1-7. UGM reconstituted with 
5-deaza-FAD (lacking the flavin N5) was unable to demonstrate any cleavage of the anomeric C1 
- O (UDP) bond, suggesting that the reaction is unable to proceed without the presence of the N5 
of flavin.26,27 In the crystal structures of UGM, solved with the substrate (to be discussed later), 
the N5 of reduced FAD (FADred) is poised for the nucleophilic attack on the C1 anomeric carbon; 
electron density observed between N5 and C1 provides further evidence in favor of the 
nucleophilic attack.24,28 
12 
 
 
 
Figure 1-7: SN2 mechanism proposed for the reaction catalyzed by UGM.7  
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1.7.3 Structure of prokaryotic UDP-galactopyranose mutases 
            X-ray crystallography was used to gain insights into the structure of UGM. So far, the 
crystal structure of a variety of prokaryotic and eukaryotic UGMs has been determined, and the 
structure has been well examined. The first crystal structure determined was that of EcUGM, 
solved to 2.4 Å, without the substrate (Figure 1-8). Each monomer unit can be divided into three 
domains, with a flexible loop and a bound molecule of the cofactor FAD.23             
 
Figure 1-8: Crystal structure of prokaryotic EcUGM.8  
The three domains and the mobile loop are highlighted for the EcUGM crystal structure (PDB id: 
1I8T); Domain 1 (blue) Domain 2 (green) and Domain 3 (gray). FAD (white stick model) is shown 
in Domain 1.  
 
Domain 1 has the FAD binding Rossmann fold, made up of the unique βαβ motif. This 
domain is common among proteins that bind nucleotides such as nicotinamide adenine 
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dinucleotide (NAD), nicotinamide adenine dinucleotide phosphate (NADP) and FAD.29,30 A 
number of conserved residues serve to bind FAD, mainly by hydrogen bonding interactions. The 
isoalloxazine ring of FAD is located at the top of a large cleft, below Domain 1, and is oriented to 
face domain 2. The α-helical Domain 2 lies below the cleft, opposite to Domain 1. This domain 
has five helices and a long, highly flexible loop. Domain 3 has six β-strands forming an antiparallel 
β-sheet, which connects Domains 1 and 2 and seals one end of the cleft formed in the front. The 
substrate was proposed to bind in the cleft region. Two identical monomer units of the enzyme 
form contact through some non-conserved residues in Domains 2 and the enzyme exists as a 
homodimer.  
The crystal structure of KpUGM and M. tuberculosis (MtUGM) were solved later and 
showed similar overall structures and domain organization, despite their moderate sequence 
identity to EcUGM, as shown in Figure 1-9.31 The structures of KpUGM solved with FAD in the 
oxidized form (FADox) and FAD in the reduced form (FADred) were also similar, except for the 
small yet significant changes in the FAD puckering. In the FADox structures, the isoalloxazine ring 
of FAD was planar compared to the bent conformation (butterfly-shaped) observed in the FADred 
structures; the N5 of FAD is sp2 and sp3 hybridized in the FADox and FADred structures 
respectively.24,31  
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Figure 1-9: Sequence identity of UGM from different bacterial species.9 
The sequence alignment was performed using ESPript (Version 3.0). The conserved residues are 
in red blocks (white letters).  
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  DrUGM, MtUGM, and KpUGM were co-crystallized with the substrate UDP-Galp.24,28,32 
These crystal structures allowed for the determination of the substrate binding mode of prokaryotic 
UGMs and the changes undergone by the enzyme when binding the ligands. The substrate binds 
to the active site, in the cleft below the isoalloxazine ring of FAD. Substrate recognition and 
interaction are conserved among UGMs, and each domain contributes residues that recognize the 
different regions of the substrate. Two residues from the fourth helix of domain 1, a conserved 
phenylalanine and tyrosine (Tyr), serve to stack the uracil. The substrate diphosphate is held by 
hydrogen bonding interactions with two conserved arginines. One arginine is contributed by 
Domain 3 while the other moves in with the mobile loop, which seals the active site completely 
by moving into a closed conformation in the presence of substrate. This is a common feature seen 
in all UGMs studied thus far.33 The substrate sugar (Galp) is held below the FAD through hydrogen 
bonds made with the Galp hydroxyls.  
 
1.7.4 Structure of eukaryotic UDP-galactopyranose mutases  
            The three-dimensional crystal structure of eukaryotic UGMs from A. fumigatus (AfUGM) 
and Trypanosoma cruzi (T. cruzi; TcUGM) were solved recently.34-37 Eukaryotic UGMs have a 
similar overall fold and domain organization to the prokaryotic UGMs, despite low sequence 
identity.37 The three domains described in prokaryotic UGMs also exist in eukaryotic UGMs 
(Figure 1-10). However, the monomer units of eukaryotic UGMs are larger in size and have 
regions of insertions in all domains, owing to their longer amino acid sequence (approximately 
100 residues longer). Unlike prokaryotic UGMs, that exist as homodimers (with the exception 
to DrUGM), the two eukaryotic UGMs display different monomeric states. A helix inserted on the 
C-terminus of domain 1 allows AfUGM to exist as a tetramer; TcUGM, which lacks this helix, 
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exists as a monomer.33 Perhaps one of the more significant insertions in eukaryotic UGMs is that 
of a helix in Domain 2, which introduces a second mobile loop in the monomer unit that leads to 
significant differences between the UGM classes.  
 
Figure 1-10: Crystal structure of eukaryotic AfUGM.10  
Three domains, Domain 1 (blue) Domain 2 and Domain 3 (gray) are highlighted. The substrate 
UDP-Galf (white stick model in Domain 2) and FAD (white stick model in Domain 1) are also 
shown (PDB id: 3UKA). 
 
Most features of substrate binding are common to both classes of UGMs; the substrate 
binds in the cleft created by the domains, and most of the active site residues are conserved across 
both UGM classes. However, more positional changes are required for the substrate binding 
residues of eukaryotic UGMs to accommodate UDP-Galp. The active site of prokaryotic UGMs 
is more or less set before the substrate comes in and minimal changes are required to bind the 
substrate in the productive conformation. There are also some differences in the substrate binding 
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mode. The uridine and the α-phosphate of the substrate UMP, are held at a tilted angle in the active 
site of eukaryotic UGMs.33 Other minor differences can also be pointed out. In the uridine-binding 
region of eukaryotic UGMs, a glutamine residue (Gln107 in AfUGM) that forms hydrogen bonds 
with the uracil ring is located under two tyrosines. In prokaryotic UGMs, the uracil ring is stacked 
in between aromatic residues, and there is no residue performing a role similar to that of glutamine. 
These differences arise due to the structural changes in eukaryotic UGMs, but as observed in 
prokaryotic UGMs, they ultimately aid in the positioning of Galp under the FAD cofactor. 
 
1.7.5 Comparison between prokaryotic and eukaryotic UDP-galactopyranose mutases - 
mobile loop flexibility 
Prokaryotic UGMs have one mobile loop while eukaryotic UGMs have two. The mobile 
loops are solvent exposed and stay in an open conformation until the substrate enters the active 
site. In prokaryotic UGMs, upon arrival of the substrate, the mobile loop moves to donate a crucial 
arginine (~ 7-11 Å shift in Cα positioning) which stabilizes the α-phosphate.24 In some structures, 
this residue also hydrogen bonds with the C3 hydroxyl of the sugar, thus forming the 'closed 
conformation' of the mobile loop. Some residues in the loop, including this arginine, form a short 
helix which allows for further stabilization of the loop.  The helices in the lower region of Domain 
2 move in the direction of the active site (by ~ 3 to 8 Å) (Figure 1-11A). This movement and the 
stabilization of the mobile loop showcase the enzyme’s ability to bind and bury the substrate 
completely in the active site. 
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(A)   
 
(B)  
 
Figure 1-11: A comparison of the loops in both prokaryotic and eukaryotic UGMs.11  
(A) Prokaryotic UGMs have a single flexible loop shown in open conformation (in green) and 
closed conformation (in magenta) in the presence of substrate (PDB id: 1I8T). The blue arrow 
shows how Domain 2 moves to close the active site. (B) Eukaryotic UGMs have two flexible 
loops, shown in closed conformation since the substrate is present in the active site (PDB id: 
3UKA). 
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Apart from mobile loop 1, eukaryotic UGMs have a second loop (mobile loop 2) located 
on top of the extra helix of Domain 2, which moves towards the active site in the presence of the 
substrate (Figure1-11B). In this case, the movement is restricted to the two mobile loops, while 
only little change occurs in the positioning of the adjacent domain helices. Like the prokaryotic 
UGMs, loop 1 (Cα of Arg182 moves ~ 11 Å in AfUGM) moves to stabilize the substrate α-
phosphate. Significant movement (~ 14 Å shift in Cα positioning of Pro206 of AfUGM) is also 
observed in loop 2, which brings in Asn207 (AfUGM) into the active site.35 This asparagine residue 
hydrogen bonds with the O4 hydroxyl of the Galp sugar. Both loops move to bury the substrate 
completely in the active site of the enzyme.  
 
1.7.6 Mutation and modeling studies on UDP-galactopyranose mutases 
  Before crystal structures with ligands were obtained, modeling, molecular dynamics, and 
docking studies were able to predict the mobile loop movement to form the open and closed 
conformations and the significance of the arginines that stabilizes the phosphate.38-40 Over the 
years, a number of mutants were created using site-directed mutagenesis (SDM); crystal structures 
of some of these mutants were solved with ligands and kinetic assays were conducted to describe 
the importance of these critical residues in the active site of UGMs from both classes. The two 
arginines that stabilize the di-phosphate of the substrate were mutated in both prokaryotic UGMs 
and eukaryotic UGMs. KpUGM R174A mutant (arginine from mobile loop 1) inactivated the 
enzyme completely, while AfUGM R182A mutant displayed significantly reduced efficiency.35,40 
This shows that the arginine residue is more important in prokaryotic UGMs while eukaryotic 
UGMs have other residues that help in stabilizing this phosphate. Both KpUGM R280A and 
AfUGM R327A (arginine that stabilizes the ß-phosphate) mutations resulted in no detectable 
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activity. AfUGM R182K and AfUGM R327K mutants displayed 10 to 70 fold less efficiency 
compared to the wild-type enzyme. The crystal structure of AfUGM R327K shows that the 
substrate is still able to bind in the productive conformation.35 However, the crystal structure of 
AfUGM R327A displays the substrate bound in a non-productive conformation, with the anomeric 
carbon of the sugar further away from the N5 of the isoalloxazine ring of FAD. Other active site 
residue mutants of EcUGM and KpUGM were studied to understand the importance of these 
residues to the active site. In KpUGM, the tyrosines which help in the stabilization of the substrate 
diphosphate were mutated to phenylalanines. It was observed that the mutation only decreased 
substrate binding considerably, but did not inactivate the enzyme.40 
 
1.7.7 Inhibitors of UDP-galactopyranose mutase 
 Since UGM is a potential drug target, a significant amount of work has been dedicated to 
identifying and validating inhibitors for the enzyme. Generally, the approach for developing 
inhibitors involves synthesizing substrate analogs or identifying lead compounds through virtual 
screening of compound libraries. A number of groups have designed and synthesized substrate-
like inhibitors of UGM. A variety of sugar-based inhibitors, uridine-based derivatives, fluorinated 
exo-glycal compounds and fluorine substituted sugar-based compounds, and substrate analogs 
have been studied.41-50 The fluorine substituted compounds mostly served the purpose of gaining 
insight into the mechanism of UGM function and were poor substrates. Most of the inhibitors 
mentioned above did not show satisfactory inhibition against bacterial UGMs. The few that 
displayed inhibition against bacterial UGMs (EcUGM, KpUGM, and MtUGM) were in the 
millimolar to micromolar range.50 Due to their polarity, low cell permeability, and cytotoxicity, 
further improvement of these compounds is required. Compounds obtained from screening 
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libraries, containing the 5-arylidene-2-thioxo-4-thiazolidinone core (Figure 1-12), aminothiazole 
core and the more recently discovered triazolothiadiazine series have shown moderate inhibition 
of UGM.51-53 Although these compounds were found to thwart bacterial growth, some compounds 
such as the aminothiazole core compounds were found to be toxic to human cells.54  
                                                  
                                              
Figure 1-12: 5-arylidene-2-thioxo-4-thiazolidinone core based UGM inhibitor.12 
 
1.8 Active sites of prokaryotic and eukaryotic UDP-galactopyranose mutase 
Since understanding the substrate binding of pyranose-furanose mutases is the theme of 
this thesis work, it is important to discuss what is previously known about substrate binding in 
these mutases. The majority of our knowledge arises from UGM, this part of the introductory 
chapter will strive to provide a comparison of substrate binding modes of UGM, based on crystal 
structures solved from prokaryotic and eukaryotic organisms. A comparison of the conserved 
active site residues of prokaryotic UGMs, such as EcUGM, KpUGM, and MtUGM, and eukaryotic 
Af UGM are shown in Table 1-1. 
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Table 1-1: Comparison of active site residues of various UGMs.1 
EcUGM KpUGM MtUGM AfUGM 
H56 H60 H65 H63 
H59 H63 H68 F66 
N80 N84 H89 R91 
L147 F151 F157 F158 
I148 F152 V158 M159 
Y151 Y155 Y161 Y162 
T152 T156 T162 N163 
W156 W160 W166 W167 
R170 R174 R180 R182 
Y181 Y185 Y191 P206 
F182 F186 F192 N207 
N268 N270 N282 Y317 
R278 R280 R292 R327 
E298 E301 E315 E373 
Y311 Y314 Y328 Y419 
R340 R343 R360 R447 
Y346 Y349 Y366 Y453 
D348 D351 D368 N457 
M349 M352 M369 Q458 
 
KpUGM and MtUGM have both unliganded crystal structures and those that were 
complexed with UDP-Galp, for prokaryotes UGMs.28,31,32 A comparison of these structures has 
indicated the changes in the α-helical domain (Domain 2) and those undergone by some of the 
active site residues in order to bind and bury the substrate within the active site. Likewise, in the 
case of eukaryotic UGMs, crystal structures of AfUGM have been solved with and without the 
substrate in the active site.35 
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A comparison of the liganded and unliganded crystal structures can help understand the 
changes that happen to the active site, when the substrate approaches the active site of UGM. 
Domain 2 re-orients to accommodate the uridine portion of the substrate and this triggers the 
mobile loop to form the closed conformation and bury the substrate within the active site. The five 
helices of this helical domain, α4, α5, and α6 and a small loop connecting helices α4 and α5 
function as a flexible hinge. The crystal structure of MtUGM with UDP-Galp is a good example.32 
The Domain 2 helices have moved towards the UDP of the substrate while this movement is not 
observed in the unliganded structure, as shown in Figure 1-13. Additionally, a new helix (helix 
α8) is formed by residues of the mobile loop.32  
 
Figure 1-13: An overlay of liganded and unliganded crystal structures of MtUGM.13  
MtUGM with UDP-Galp (green) and without UDP-Galp (purple) are shown, highlighting the 
important changes occurring in the α-helical domain, on the arrival of the substrate (PDB id: 1VOJ 
& 4RPG).  
 
UDP-Galp 
Helix α4 
Helix α6 
Mobile loop 
Mobile loop 
Helix α5 
Helix α8 
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The movement of the mobile loop towards the substrate is expected to close the otherwise 
open substrate binding site (~ 67 % closure as estimated from MtUGM structure). Apart from 
bringing in Arginine, which stabilizes the α-phosphate, the mobile loop also brings in hydrophobic 
residues, which form a hydrophobic pocket that helps in positioning the substrate uridine, as shown 
in Figure 1-14A.32  
(A)               (B) 
 
Figure 1-14: Movement of the mobile loop in the presence and absence of UDP-Galp.14   
(A) The changes in position of active site residues Leu181, Arg180, Ile178 and Leu173, when the 
mobile loop moves towards active site in the presence (green) and absence of substrate (purple)   
(B) The changes in positioning and interactions of residues hypothesized to trigger closure of the 
loop in the presence (green) and absence (purple) of UDP-Galp (PDB id: 1VOJ & 4RPG). 
 
Apart from the domain movement, the presence of the substrate in the UGM active site 
also induces local changes in the orientation of residues close by. A tryptophan residue in helix α6 
Trp166 
Arg261 
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rotates and forms hydrogen bonds with the substrate ribose. This movement breaks its cation-π 
interaction with an adjacent arginine causing it to rotate back by 180° and form hydrogen bonds 
with residues nearby. The break in cation-π interaction between Trp166 and Arg261 that occurs 
during MtUGM substrate binding is shown in Figure 1-14B. The conserved nature of these residues 
and their positioning in semi-closed and unliganded structures in prokaryotic UGMs lends support 
to the hypothesis that the movement of these residues could potentially trigger the closure of the 
active site. 
The movement of the α-helices towards the substrate also means the residues have moved 
further closer to the uridine moiety. Additional changes in the orientation of residues aid in 
positioning and binding of the uridine moiety. Among these residues, only a tyrosine and 
asparagine are highly conserved in all prokaryotic UGMs. As shown in Figure 1-15, in MtUGM, 
Tyr161 rotates ~ 45º and forms cation-π interactions with the uracil and the side chain of Asn282 
flips ~ 180º to form hydrogen bonds with the O4 of the uracil ring. A number of different 
nonconserved residues such as phenylalanine, valine, isoleucine and leucine also aid to position 
the uracil ring in a hydrophobic pocket in prokaryotic UGMs. 
The mobile loop brings an arginine that stabilizes the α-phosphate. In most cases the 
guanidium moiety of this residue can enable the stabilization of the β-phosphate. Additionally, 
there are three tyrosines residues which are in position to interact with the substrate diphosphate. 
Earlier these tyrosines were hypothesized to interact with the sugar hydroxyls, but these evidences 
show their role in stabilizing the phosphates. These residues are highly conserved in all the 
prokaryotic UGMs. In Figure 1-16, Tyr366 which moves ~ 5-6 Å and rotates ~ 90º to stabilize the 
β-phosphate, while also forming a cation-π interaction with Arg180, to maintain the closed 
conformation of the mobile loop in MtUGM, is shown. 
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Among the prokaryotic UGMs, there are small differences in the active site residues and 
their interactions with the sugar portion of the substrate.  In MtUGM and DrUGM, the mobile loop 
arginine forms hydrogen bonds with the 2-OH group of the substrate sugar (Galp), while this 
interaction is not observed in KpUGM.24,28,32 The Galp 3-OH is often stabilized by interactions 
with a conserved histidine residue in bacterial UGMs, such as MtUGM His68. Another histidine 
residue that interacts with Galp 6-OH in MtUGM is replaced by an asparagine in KpUGM. The 
incoming substrate triggers the movement of a nearby six-residue loop, towards the adenine moiety 
of FAD. This loop movement causes another conserved arginine, to re-orient towards the active 
site and form water-mediated hydrogen bonds with Galp 2-OH (Figure 1-17). 
 
Figure 1-15: The uridine-binding region of MtUGM.15 
The changes in positions of residues in the absence (purple) and the presence of UDP-Galp (green) 
are highlighted (PDB id: 4RPG). 
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Additionally, the O4 of FAD hydrogen bonds with the C4 hydroxyl of Galp. This 
interaction aids in substrate selectivity by UGM; the enzyme does not recognize UDP-Glup with 
the C4 hydroxyl in an equatorial position.28 The substrate bound structures have also generated 
vital information about the non-productive and productive modes of substrate binding when the 
FAD is in the oxidized and reduced forms, respectively. In the productive binding mode, the N5 
of the isoalloxazine ring of FAD is located within a range of 2.9 to 4.0 Å, from the anomeric carbon 
of the sugar (Galp), as shown in Table 1-2. The productive mode is observed in the substrate bound 
FADred structures.
24 In the non-productive mode, seen in FADox structures of various UGMs, this 
distance is greater than that noted in the substrate bound FADred structures. 
 
 
Figure 1-16: The phosphate-binding region of MtUGM.16  
The changes in the positioning of residues in the absence (purple) and the presence of UDP-Galp 
(green) are highlighted (PDB id: 4RPG). 
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.  
Figure 1-17: The sugar-binding region of MtUGM.17  
The changes in the positioning of residues in the absence (purple) and the presence of UDP-Galp 
(green) are highlighted (PDB id: 4RPG). 
 
 
Table 1-2: A comparison of distances between the N5 of the isoalloxazine ring of FAD and 
the C1 of Galp from oxidized and reduced crystal structure of various UGMs.2 
 FADox N5 - C1 Galp distance (Å) FADred N5 - C1 Galp distance (Å) 
Prokaryotic UGMs   
MtUGM 4.2* 3.9 - 4.0 
KpUGM 7.8 - 8.0 3.6* 
DrUGM 3.4 - 3.7 2.9 -3.2 
Eukaryotic UGMs   
AfUGM 5.2* 3.6* 
* Values are taken from a single monomer unit of the enzyme. 
UDP-Galp 
Arg180 
Arg360 
Arg360 
His89 
His89 
His68 
His68 
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Figure 1-18: The active site residues of KpUGM.18  
The active site residues (cyan) in the presence of substrate UDP-Galp and FAD are shown as white 
sticks (PDB id: 3INR). 
 
The substrate binding site of KpUGM, in the presence of UDP-Galp, resembles that of the 
MtUGM: UDP-Galp active site, shown in Figure 1-18. Although minor differences exist in terms 
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of the residues that make up this site, it is noted that its overall structure and the substrate binding 
mode are largely conserved. Furthermore, the changes that occur in the enzyme, to accommodate 
the substrate in the active site is also very similar across bacterial UGMs as evidenced by crystal 
structures.33 Also, the active site of prokaryotic UGMs is comparable to that of eukaryotic UGMs. 
From Table 1-1, the active site residues are similar if not entirely conserved. However, since 
eukaryotic UGMs have two mobile loops change to a closed conformation, to bury the substrate 
in the active site, the functioning of Domain 2 is expected to be different in this case.  
Among the eukaryotic UGMs, although crystal structures are available for AfUGM and 
TcUGM, both unliganded and UDP-Galp bound structures are available for only AfUGM. The 
TcUGM crystal structures were solved with UDP in the active site.36 Although there is not as much 
re-orientation of the helices in Domain 2, significant changes occur in the conformation of the two 
flexible loops and the helix that connects them, as shown in Figure 1-19. An analysis of the 
structures suggest that the movement two flexible loops, brings the residues in place to interact 
with the uridine moiety of the substrate.35  
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Figure 1-19: Domain 2 of AfUGM in open and closed configuration.19  
The open loop configuration, without the substrate in the active site, and closed loop configuration 
with the substrate in the active site are shown in purple and burgundy respectively (PDB id: 3UKA 
& 3UKH). 
 
 In the eukaryotic UGM active site, two tyrosine residues stack the uracil, while 
hydrophobic residues such as proline and phenylalanine aid in positioning it. An additional 
glutamine residue which moves further into the active site and forms hydrogen bonds with the 
uracil, is not observed in any prokaryotic UGMs. The closed loop conformation of Loop 2 is 
stabilized by a highly conserved arginine, which rotates towards Loop 2 and forms hydrogen bonds 
with the side chains of residues such as tyrosine and some adjacent residues which ends Loop 2, 
as shown in Figure 1-20.  
UDP-Galp 
Loop1 
Loop2 
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Loop2 
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As already seen with prokaryotic UGMs, Loop 1 in eukaryotic UGMs also contributes 
hydrophobic residues that aid in positioning the substrate uridine and a negatively charged arginine 
residue that stabilizes the α-phosphate. This residue also makes additional interactions to stabilize 
the closed loop conformation, as seen in prokaryotic UGMs. Arg182 of AfUGM forms cation-π 
interaction with Tyr453. In the phosphate binding region, another highly conserved arginine, 
moves into position to stabilize the β-phosphate. 
 
Figure 1-20: The movement of AfUGM residues that bind the substrate uracil.20  
Tyr104, Pro105, and Gln107 that bind the substrate uracil are shown in burgundy, in the presence 
of substrate. The movement of Arg91 to aid stabilization of Loop 2 is shown in the absence and 
presence of the substrate in purple and burgundy respectively (PDB id: 3UKA & 3UKH). 
 
The sugar binding region of eukaryotic UGMs are also comparable to prokaryotic UGMs. 
The sugar is held in the same orientation as seen with the prokaryotic UGMs. In AfUGM, residues 
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such as Asn207, Asn447, and Arg327 hydrogen bond with C3, C4 and C6 hydroxyls of Galp, 
while Arg447 interacts with the C2 hydroxyl by a water-mediated hydrogen bond. The overall 
substrate binding site of AfUGM is similar to prokaryotic UGMs, as shown in Figure 1-21. It is 
also noted that the N5 of FADred is ~3.7 Å away from the Galp C1 carbon while the N5 of FADox 
is ~5.2 Å away from the Galp C1 carbon (Table 1-2). 
 
Figure 1-21: A close-up of the active site residues of eukaryotic AfUGM.21  
The active site residues (burgundy) in the presence of substrate UDP-Galp and FAD are shown as 
white sticks (PDB id: 3UKH). 
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1.9 Other pyranose-furanose mutases 
 Until now, only a handful of enzymes has been identified and characterized to perform the 
pyranose-furanose interconversion reaction. Perhaps the best studied among these enzymes after 
UGM is UDP-N-acetyl galactopyranose mutase (UNGM), which functions to interconvert 
between UDP-N-acetyl galactopyranose (UDP-D-GalpNAc) and UDP-N-acetyl galactofuranose 
(UDP-D-GalfNAc).55 The enzyme was identified as a gene product of cj1439c (a homolog of the 
glf gene), identified in C. jejuni strain 11168.56 Initial characterization of UNGM was performed 
by Dr. Todd Lowary's group (University of Alberta) and crystallization and structural studies were 
completed by Dr. Sean Dalrymple and Carla Protsko, previous members of the Sanders group. 
UNGM is also a flavoenzyme and has a high sequence identity with bacterial UGMs (EcUGM, 
KpUGM, DrUGM, and MtUGM). Unlike UGM, UNGM is a bifunctional enzyme and can 
recognize both UDP-D-Galp and UDP-D-GalpNAc as substrates. The crystal structure of UNGM 
with UDP-D-Galp shows that most of the UNGM active site residues are similar to those from 
bacterial UGMs, except an arginine residue (Arg59) which interacts with the acetamido group of 
UDP-D-GalpNAc.57 GaHM is another flavin-containing pyranose-furanose mutase that has been 
identified in C. jejuni. This enzyme is different from the mutases described so far, as it is 
hypothesized to require a GDP based substrate, and interconverts between a heptopyranose (7-
carbon chain) and a heptofuranose.58 Though they catalyze similar pyranose-furanose 
interconversions, these mutases have low sequence identity, as shown in Figure 1-22. 
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Figure 1-22: Low sequence similarity among the pyranose-furanose mutases.22   
EcUGM and C. jejuni UNGM (CjUNGM) have a higher identity with each other than C. jejuni 
GaHM (CjGAHM) or OsUAM. Among all the four sequences OsUAM has the least sequence 
similarity with any of the other enzymes. The sequence alignment was performed using ESPript 
(Version 3.0). The conserved residues are in red blocks (white letters).  
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Reports describing the identification and characterization of pyranose-furanose mutases 
from other organisms have emerged recently. The gene Fcf2 from E. coli O52 encodes for a 
pyranose-furanose mutase that works in the pathway that synthesizes deoxy thymidine-di 
phosphate–D-fucofuranose (dTDP-D-Fucf).59 This enzyme interconverts between thymidine-di 
phosphate–D-fucopyranose (dTDP-D-Fucp) and dTDP-D-Fucf. Its 40-60% DNA sequence 
identity with UGMs and the protein sequence alignment has identified the presence of an ADP-
binding fold that can bind FAD. Thus, the gene product of Fcf2 was proposed to be an FAD-
requiring mutase that belongs to the UGM family.59 However, more research has to be conducted 
to understand substrate binding and how the active site is modified, as compared to other UGMs. 
An enzyme that is perhaps the most different to any of these mutases is UAM, a metalloenzyme 
that does not require FAD for performing its function.18 The next part of this chapter will introduce 
UAM and GaHM since apart from UGM, this thesis will discuss results pertaining to both these 
enzymes. 
 
1.9.1 UDP-arabinopyranose mutase  
 UAM is a pyranose-furanose mutase that functions in the plant cell wall. UAM works in a 
pathway that leads to the deposition of L-Araf residues in the cell wall. Even though the importance 
and abundance of L-Araf residues in the plant cell wall is well documented, complete details about 
the biosynthetic pathway that leads to the deposition of L-Araf residues in the cell wall have only 
emerged recently.8,18,60,61  
Among the common nucleotide sugars identified in a plant cell, the biosynthesis of UDP-
Arap is well understood. Since only UDP-Arap was previously detected in a plant cell wall, it was 
considered to be the potential precursor for L-Araf residues.62 However, experiments conducted to 
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investigate the theory failed to lend support to this argument. When UDP-Arap was used as the 
substrate donor for arabinosyltransferases, Arap was transferred onto arabino-oligosaccharides.61 
This meant that plants might require UDP-Araf for biosynthesis of arabinofuranosides. (1, 5) α-L-
arabino-oligosaccharides were successfully synthesized in vitro by mung bean arabinofuranosyl 
transferase extracts using UDP-Araf as the substrate.63 Though this study provided evidence for 
the production and requirement of UDP-Araf in the plant cell wall, the point of isomerization of 
Arap to Araf in the biosynthesis pathway was still unknown. 
  It was demonstrated that plants employ UAM for the conversion of UDP-Arap to UDP-
Araf (Figure 1-23). UAM activity was first identified in rice seed extracts, based on their ability to 
synthesize UDP-Araf from UDP-Arap. The reaction catalyzed by UAM is reversible with the 
equilibrium favoring the formation of UDP-Arap in a 9: 1 ratio.18 
 
Figure 1-23: A schematic of the reaction catalyzed by UAM.23 
 
Although the reaction catalyzed by UAM is similar to the one catalyzed by UGM, these 
plant mutases neither bind FAD nor is it required for activity.18 The purified Oryza sativa (O. 
sativa, rice) UAM (OsUAM) did not have the characteristic flavin UV-absorption peak at 450 nm. 
Furthermore, it was observed that OsUAM required divalent metal ions for activity. Although 
UAM was active on UDP-Galp, the substrate of UGM, it was only a fraction of the activity 
compared to the activity obtained with UDP-Arap. UAM was also identified in mung bean 
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extracts. The presence of UAM encoding genes in a variety of plant species ranging from green 
algae such as Chlamydomonas reinhardtii, mosses such as Physcomitrella patens to various dicots 
and monocots, indicates that UAM is widespread among plants and has a vital role in cell wall 
biosynthesis.18 
Plant mutases belong to a small gene family called Reversibly Glycosylated Polypeptides 
(RGPs), meaning they can be reversibly auto glycosylated by UDP-sugars such as UDP-galactose, 
UDP-xylose, and UDP-glucose.64,65 RGPs are highly conserved proteins, implicated in 
polysaccharide biosynthesis and defense responses and have been identified in the membrane and 
soluble fractions of plant species such as arabidopsis, pea, cotton, maize, potato, wheat, rice, and 
tomato.66 Their identification in only plants (monocots and dicots) thus far shows that RGPs maybe 
plant-specific proteins.  The three UAM genes that were identified from O. sativa are also RGPs; 
out of the three genes only two, OsUAM1 and OsUAM3, have the arabinofuranose-pyranose 
interconversion function while the third enzyme, OsUAM2 does not display this ability.18 More 
recently, five RGP genes have been discovered in Arabidopsis thaliana (A. thaliana); three of 
these proteins, RGP1, RGP2 and RGP3 (AtRGP1, AtRGP2, AtRGP3) have UAM function, i.e. 
catalyze the interconversion between UDP-Araf and UDP-Arap, while the other two, RGP4 and 
RGP5 (AtRGP4 and AtRGP5) do not.66  
UAM activity is critical for the production and cell wall deposition of L-Araf in plants. 
Gene knockout studies were used to demonstrate the importance of UAM activity in plant cells.66 
An analysis of cell wall monosaccharides of cell lines that had AtRGP1 and AtRGP2 genes 
knocked out, led to the observation of a 30 % reduction in total leaf cell wall arabinose content.66 
Moreover, in cell lines where the expression of these genes was suppressed, there was a massive 
reduction (~ 80 %) in the cell wall arabinose content and the UAM activity was reduced to ~ 1 % 
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of the wild-type.66 A similar trend was also observed in cells involved in pollen development and 
seed coat secretion, thus proving the importance of UAM activity to the plant cell wall. 
All three rice UAMs (OsUAMs) identified are ~ 39 - 41 kDa proteins. OsUAM1 and 
OsUAM3 share 88% sequence identity, while OsUAM2 shares only ~ 46% identity with OsUAM1 
and OsUAM3.18 Moreover, when treated with radiolabeled UDP-[14C]-glucose, OsUAM1 and 
OsUAM3 were both auto glycosylated, but OsUAM2 lacked this ability. Also, the auto 
glycosylation is deemed reversible, since the [14C]-glucose could be replaced with any among 
xylose, galactose or arabinose depending on which UDP-sugars reacted with UAM. If OsUAM 
was incubated with any among UDP-Glc, UDP-Xyl, or UDP-Gal for up to 6 hours, before the 
addition of UDP-Araf, up to 50% reduction in mutase activity was observed.18 
The molecular weight of UAM, prepared from rice seedling extracts, estimated by Konishi 
et al., (2007) using size-exclusion chromatography was ~ 460 kDa, indicating that its oligomeric 
state had to be at least a decamer. Rice UAM achieved optimal activity at a temperature of 55 ºC; 
maximum UDP-Araf formation was observed between pH 7.0 and 7.5 while maximum UDP-Arap 
formation was seen between pH 5.5 and 6.0. The enzyme had a higher affinity for UDP-Araf (Km 
= 55 µM) than EcUGM (Km = 600 µM).  
The AtRGPs had molecular weights in the range of 38 - 41 kDa.66 AtRGPs 1 and 2 
overexpressed in growth tissues where cell wall components needed to be synthesized. Their 
importance in cell wall development was demonstrated when double knock-out mutants failed to 
develop cell wall polysaccharides and had severe growth retardation. Since AtRGP1 and AtRGP2 
have the highest sequence identity, it was considered that their function was redundant. In their 
study, Rautengarten et al., (2011) discovered that knocking out either one of these two genes (rgp1 
or rgp2), led to significantly less arabinose synthesis. In plant cells, AtRGP1 and AtRGP2 are 
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localized in the cytoplasm and in Golgi compartments where they are required for cell wall 
polysaccharide biosynthesis. AtRGP3 was found in cytosolic fractions. The ability to auto 
glycosylate was also observed in AtRGPs that possess the mutase interconversion function. 
 
1.9.2 GDP-6d-altro-heptopyrnaose Mutase  
  The gram-negative bacterium, C. jejuni is the leading cause of diarrhea, causes intestinal 
illness, gastroenteritis and is also linked to the neurological disorder Guillian–Barré syndrome and 
its variant, Miller Fisher syndrome, in humans.19,67 Though the LPS layer is associated with the 
many diseases caused by C. jejuni, the more recently identified CPS has been considered important 
for virulence of the bacterium.68,69 The CPS is composed of a variety of sugars in both pyranose 
and furanose forms. C. jejuni HS: 41 serotype, isolated from patients with Guillian–Barré 
syndrome, has a trisaccharide repeat unit in its CPS, composed of four different furanose residues. 
One of the furanoses in this repeating unit is 6d-D-altro-Hepf.70 The CPS gene locus of C. jejuni 
HS: 41 serotype has homologs of the glf gene (the gene that encodes for UGM) which encodes 
other mutase enzymes that may synthesize the precursors required for the production of the 
trisaccharide unit. Three homologs of the glf gene, namely glf1, glf2 and glf3 were identified in 
this gene locus.71  
The gene product of glf1 is proposed to function as a GaHM by Dr. Todd Lowary's group 
(University of Alberta). The results of their experiments conclude that recombinant GaHM is an 
enzyme that synthesizes GDP-6d-D-altro-Hepf, the precursor of 6d-D-altro-Hepf (Figure 1-24). 
Although most mutases studied thus far use a UDP-based substrate for the interconversion 
reaction, it is believed that GaHM uses a GDP-based substrate and does not bind to a UDP-based 
substrate. This hypothesis was based on the identification of the hddC gene (D, D-heptose-1-
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phosphate guanylyltransferase) in the CPS gene locus, known to be responsible for biosynthesis 
of another GDP-heptose sugar, in C. jejuni strain 11168.71 Since GaHM is the gene product of a 
glf - like gene and a flavoenzyme, it is expected to have characteristics more similar to UGMs and 
UNGM, than to plant UAMs.  
 
 
Figure 1-24: A schematic of the reaction catalyzed by GaHM.24 
 
1.10 Objectives of the Research 
The three pyranose-furanose mutases described in the previous section (UGM, UAM, and 
GaHM) is the topic of this investigation. The over-arching theme of the research performed in this 
thesis is to understand the binding of the substrate to the active site of these enzymes and to 
understand how changes in the active site of the enzymes affect substrate binding. Among the three 
enzymes, UGM is the most studied while the other two enzymes are not as well understood, 
perhaps because they have only recently been identified. The structure of UGM (from both 
prokaryotic and eukaryotic organisms) and the structural basis for substrate recognition are known. 
However, apart from some of the active site residues, which have obvious importance in 
recognizing and binding different regions of the substrate, the structural role of other active site 
residues have not been studied in any of the known UGMs. The importance of these residues in 
maintaining the structure of the active site cavity in the correct conformation and the manner in 
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which they ensure the productive binding mode of the substrate are not understood thus far. To 
accomplish this goal, DrUGM was chosen and six active site point mutants were created using 
SDM. Experiments were conducted on these mutants to gain input into how these mutations may 
affect the substrate binding in UGM. 
OsUAM1 was first identified, purified and characterized by Konishi et al. (2007). There is 
minimal structural and mechanistic information available on UAM. It is a non-FAD-binding 
enzyme which uses divalent metal ions for catalysis. It was demonstrated that OsUAM1 and 
AtRGPs were active when assayed in the presence of manganese (Mn2+). UAM's low sequence 
identity with UGM and metal-ion dependency could mean that its catalytic mechanism and 
substrate binding mode may be completely different to the well-studied UGM. The aim of this 
study was to gain an understanding of the active site residues involved in metal co-factor and 
substrate binding. Divalent metal ion dependency of these plant mutases was also investigated to 
make a comparative analysis among the chosen UAMs. In the case of both OsUAM1 and AtRGPs, 
no studies have yet been performed to show if there is a loss of activity in the absence of Mn2+ or 
other divalent ions. No information is available about the binding constants of the metal co-factor 
and how the metal binds and interacts with any of these enzymes. Other divalent metals were tried 
in the case of OsUAM but not AtRGPs. Obtaining such information will help to understand better 
the role the metal plays in enzyme function.  
The next pyranose-furanose mutase studied was CjGaHM, which requires the FAD 
cofactor for activity. A crystal structure of this enzyme, co-crystallized with GDP (solved by 
previous member of the Sanders lab) was already available [unpublished results]. However, GDP 
is the nucleotide base for the substrate; the goal here was to obtain structural information with a 
GDP-sugar and make a comparative analysis with UGM to understand how the active site of 
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GaHM can accommodate a GDP-based substrate rather than a UDP-based substrate (as seen in 
UGM and UAM).   
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Chapter 2: Materials and methods 
2.1 Cloning of RGPs from Arabidopsis Thaliana  
 AtRGP1 (Gene ID: 1523286, Accession no: NP_186872), AtRGP2 (Gene ID: 15242351, 
Accession no: NP_197069) and AtRGP3 (Gene ID: 30680679, Accession no:  NP_187502) were 
identified as UAMs in A. thaliana.66 Over-expression clones of these three proteins were made 
using Gateway cloning technology.72 Genes encoding each of the RGPs were synthesized and 
obtained in a pET29b plasmid. The genes were amplified using the polymerase chain reaction 
(PCR) using gene-specific primers shown in Table 2-1.  
 
Table 2-1: Primers for cloning of AtRGPs.3 
RGP1 Primer N1 5'-GAGAACCTGTACTTCCAGGGTGGTGGTATGGTGGAACCGGC – 3' 
RGP1 Primer C 5'-GGGGACCACTTTGTACAAGAAAGCTGGGTTATTAAGCTTTCGTCGGCGG - 3' 
RGP2 Primer N1 5'- GAGAACCTGTACTTCCAGGGTGGTGGTATGGTGGAACCGGCG - 3' 
RGP2 Primer C 5'- GGGGACCACTTTGTACAAGAAAGCTGGGTTATTAGGCTTTACCGCTGGC-3' 
RGP3 Primer N1 5'- GAGAACCTGTACTTCCAGGGTGGTGGTATGGCTCAACTGTAC - 3' 
RGP3 Primer C 5'- GGGGACCACTTTGTACAAGAAAGCTGGGTTATTAATTTTTACCCTTCGG -3' 
Primer N2 5'- GGGGACAAGTTTGTACAAAAAAGCAGGCTCGGAGAACCTGTACTTCCAG-3' 
.  
Primer N1 has a tobacco etch virus protease (TEV protease) recognition site on the 5' end, 
and Primer C has an attB2 recombination site on the 5'-end. PCR reactions were set up using the 
procedure, shown in the Table 2-2. PCR products obtained with the TEV-protease recognition site 
and the attB2 recombination site on the N and C-termini of the RGP gene, respectively, were gel-
purified (Gel extraction kit, Qiagen). A second PCR amplification was performed using this gel-
purified product as the template and the generic primer N2, which has a TEV-protease recognition 
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site at the 3'-end and primer C, specific for each RGP. At the end of this PCR, the AtRGP genes 
obtained contained an attB1 recombination site and a TEV-protease recognition site at the 5'-end 
and an attB2 recombination site at the 3'-end, as shown in Figure 2-1. 
 
Table 2-2: PCR reaction conditions for cloning of AtRGPs.4 
Process Temperature (°C) Time Cycles 
Denaturation 95 5 min 1 
Annealing 55 30 sec 1 
Denaturation 95 45 sec  
Annealing 55 30 sec 40 
Elongation 72 2 min  
Elongation 72 10 min 1 
Cooling 4 1 hour  
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Figure 2-1: A scheme for obtaining PCR amplified RGP gene products.25 
The RGP gene with Primer N1, Primer N2 and Primer C is shown. The Primer N1 has nucleotide 
sequence corresponding to TEV protease recognition site on its 5'-end. The Primer N2 has 
nucleotide sequence corresponding to TEV protease recognition site on its 3'-end. The Primer C 
has a stop codon on its 3'-end. The RGP gene with the primers are PCR amplified to obtain a 
product with attB1 and attB2 (attachment) sites on either ends of the RGP gene. 
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BP and LR reactions were performed sequentially, with this final PCR-product, to clone 
the AtRGPs into the destination vector. The PCR-product was initially cloned into an entry clone 
vector, pDONR-221. Both were added to a 10 µl BP reaction mixture, in the presence of the 
enzyme BP Clonase-11 (Invitrogen) and the reaction was allowed to proceed for 3-4 hours. The 
reaction products were transformed into E. coli DH5α cells (Invitrogen) and plated onto LB agar 
plates with kanamycin and grown overnight at 37 °C. A few colonies were picked and grown 
overnight, and plasmids were isolated (Qiagen mini-prep kit). Plasmids which contained the 
desired RGP genes, as verified by sequencing, were used for the LR reaction, which transfers the 
RGP genes from the entry clones to a destination vector. A LR reaction (10 µl) was set up by 
adding the pDONR-221 containing the RGP genes into the destination vector, pDEST-HisMBP, 
in the presence of LR Clonase-11 (Invitrogen). After 3 - 4 hours, the reaction product obtained 
was transformed into E. coli DH5α cells (Invitrogen), plated onto LB agar plates with ampicillin 
and grown overnight at 37 °C. A few of the grown colonies were picked, their plasmids isolated 
(Qiagen mini-prep kit) and sequenced (Applied Genomics Center, National Research Council, 
Saskatoon, Canada). Plasmids with the desired genes were then transformed into E. coli BL21 
Gold over-expression cells (Stratagene). 
 
2.2 Cloning of OsUAM1 
 The OsUAM1 gene (Gene ID: 75153246, Accession no: Q8H8T0) was cloned into a 
pHISTEV vector that encodes for proteins with a 6xHistidine tag on its N-terminal. Additionally, 
a TEV-protease recognition site is present in between the His-tag and the protein sequence for 
efficient cleaving of the His-tag. After confirmation of the required sequence, the pHISTEV 
plasmid with the OsUAM1 gene was transformed into E. coli BL21 Gold cells for over-expression. 
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2.2.1 Site-directed mutagenesis of OsUAM1 mutants 
The primers used to create OsUAM1 mutants D110A, D111A, D112A and H273A were 
designed using PrimerX and synthesized by AlphaDNA (AlphaDNA Inc.). PCR was set up using 
~50 ng of wild-type OsUAM1-plasmid DNA as template, ~ 125 ng of corresponding forward and 
reverse primers (shown in Table 2-3), dNTPs, KAPA HiFi DNA polymerase (KAPA Biosystems) 
and the reaction buffer, using the PCR reaction condition shown in Table 2-4.  
 
Table 2-3: Primers for cloning of OsUAM1 mutants.5  
Mutants Primers 
H273A Forward 5'-CGTACATCTGGGCCAGCAAGGCTAG -3' 
H273A Reverse 5'-CTAGCCTTGCTGGCCCAGATGTACG-3' 
D110A Forward 5'-GTACGTCTTCACCATCGCCGACGACTGCTTCGTTG -3' 
D110A Reverse 5'-CAACGAAGCAGTCGTCGGCGATGGTGAAGACGTAC -3' 
D111A Forward 5'-CTTCACCATCGACGCCGACTGCTTCGTTGCC -3' 
D110A Reverse 5'-GCAACGAAGCAGTCGGCGTCGATGGTGAAGG -3' 
D112A Forward 5'-CACCATCGACGACGCCTGCTTCGTTGCC-3' 
D110A Reverse 5'-GGCAACGAAGCAGGCGTCGTCGATGGTG-3' 
 
The reaction product was digested with Dpn1 at 37 °C for one hour, transformed into E. 
coli DH5α cells and plated on LB-agar plates with kanamycin and incubated at 37 °C overnight. 
A few colonies were selected and inoculated into 5 ml Luria-Bertani (LB) broth with kanamycin 
and grown overnight. The plasmid DNA was isolated (Qiagen mini-prep kit) and sent for 
sequencing, to confirm the desired mutations. The plasmid DNA was then transformed into E. coli 
BL21 over-expression cells. 
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Table 2-4: PCR reaction condition for OsUAM1 mutants.6 
Process Temperature (°C) Time Cycles 
Denaturation 95 5 min 1 
Annealing 55 30 sec 1 
Denaturation 95 45 sec  
Annealing 55 30 sec 18 
Elongation 72 2 min  
Elongation 72 10 min 1 
Cooling 4 1 hour  
 
2.3 Over-expression and purification of mutases 
2.3.1 Over-expression and purification of OsUAM1 
 BL21 Gold cells containing the plasmids encoding for the desired OsUAM1 was grown 
overnight at 37 °C in 100 ml LB media with 100 µg/ml kanamycin. 10 ml of this culture was 
subcultured into 1L cell culture flasks and left to grow at 37 °C to an OD600 of 0.6. 500 µM 
isopropyl-ß-thiogalactoside (IPTG) was added for protein over-expression, and the cells were 
allowed to grow overnight at 15 °C. The next day, cells were harvested by centrifugation at 4 °C, 
3600 rpm and stored in -80 °C. Frozen cell pellets were re-suspended in lysis buffer, containing 
50 mM sodium phosphate pH 8.0, 50 mM NaCl, 10 µg/ml DNase, 20 µg/ml lysozyme, 0.1 % 
Triton-X and 0.1 % ß-mercaptoethanol, and stirred at 4 °C for 30 minutes. This was followed by 
sonication for 3 minutes, (15 sec pulse on/off), to break open the cell wall, and centrifugation at 
15000 rpm for 30 minutes at 4 °C, to obtain soluble protein in the supernatant and to remove 
unwanted cell debris. 
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Purification was performed using nickel affinity chromatography followed by size 
exclusion chromatography. The supernatant was loaded onto a Protino Ni-IDA column 
(Macherey-Nagel), previously charged with Ni2+ and equilibrated with 50 mM sodium phosphate 
pH 8.0 and 50 mM NaCl. The column was washed with 50 mM sodium phosphate pH 8.0, 50 mM 
NaCl containing 30 mM imidazole to remove protein impurities. OsUAM1 was then eluted with 
50 mM sodium phosphate pH 8.0, 50 mM NaCl and 250 mM imidazole. OsUAM1 fractions were 
dialyzed against 25 mM Bicine pH 8.5 and concentrated to ~ 5 mg/ml before being loaded onto a 
Gel-filtration column (GE Healthcare), equilibrated with 25 mM Bicine pH 8.5. The enzyme eluted 
as a big first peak followed by other contaminating proteins. Purified UAM fractions were pooled 
and dialyzed against 25 mM Bicine pH 8.5 with 1 mM Manganese chloride and concentrated to ~ 
6.5 mg/ml, for crystal trials.  
A stock UAM concentrated to ~ 1 mg/ml was preferred for kinetic and metal binding 
assays. For kinetics, the purified protein was treated with a metal chelating agent, 200 mM 
ethylenediaminetetraacetic acid (EDTA), for 3 hours and dialyzed against 25 mM Bicine pH 8.5 
(four exchanges) prior to flash freezing with liquid nitrogen. This was done to remove any metal 
that might affect the UDP-Araf to UDP-Arap conversion during metal binding assay experiments. 
 
2.3.2 Overexpression and purification of OsUAM1 mutants 
 Four different mutants of OsUAM1; D110A, D111A, D112A, and H273A, were all over-
expressed and purified as described above and a final stock concentration of ~ 1 mg/ml was 
prepared for each, to use for kinetic assays. 
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2.3.3 Over-expression and purification of AtRGPs 
 All three AtRGPs (RGP1, RGP2, and RGP3) were over-expressed and purified following 
a similar procedure. RGP genes cloned into pDESTHis-MBP over-expression vector, expressed 
with a 6x Histidine-tagged Maltose binding protein (MBP) at the N-terminal. Cells expressing 
these proteins were grown overnight in 100 ml LB media with 100 µg/ml ampicillin at 37 °C. The 
next day, 10 ml of the overnight culture was subcultured into 1L of autoclaved LB media 
containing 100 µg/ml ampicillin. The cells were allowed to grow at 37 °C until an OD600 of 0.5 
was achieved and then protein over-expression was induced by the addition of 500 µM (final 
concentration) of IPTG and set to grow overnight at 15 °C. The cells were harvested the next day 
by centrifugation at 4 °C and 3500 rpm for 20 minutes and stored at -80 °C until further use. Cell 
lysis was done by resuspending the cells in 50 mM potassium phosphate pH 8, 50 mM NaCl, with 
20 µg/ml lysozyme and 10 µg/ml DNase for 30 minutes followed by sonication for 3 minutes, (15 
sec pulse on/off). The solution was then clarified of cell debris by centrifugation at 15000 rpm for 
30 minutes at 4 °C.  
The supernatant was loaded onto a Ni-sepharose column (GE-Healthcare), pre-equilibrated 
with buffer containing 50 mM potassium phosphate pH 8 and 50 mM NaCl. Bound His6-MBP-
RGPs were eluted out of the column with Elution buffer (50 mM potassium phosphate pH 8, 50 
mM NaCl and 250 mM Imidazole), after the impurities were removed by washing the column with 
50 mM potassium phosphate pH 8, 50 mM NaCl and 30 mM Imidazole. The His6-MBP-RGP 
fractions were pooled together, dialyzed against 50 mM potassium phosphate pH 8, 50 mM NaCl, 
to remove imidazole, and concentrated to ~ 30 mg/ml, for setting up a tag-cleavage reaction with 
TEV protease. To cleave the His6-MBP-tag, 2 mg TEV protease was added to 10 mg purified RGPs 
(a 1:5 ratio), and the reaction was left to shake at 4 °C overnight. The TEV protease digested 
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sample was then loaded onto a Ni-sepharose column (GE-Healthcare) pre-equilibrated with 25 
mM Bicine pH 8.5. The required RGP proteins (MBP-tag less) were eluted in the wash with the 
same buffer and the 6xHis-MBP-tag (which is still bound to the column due to the 6xHis tag), was 
eluted with 25 mM Bicine pH 8.5, 250 mM imidazole. The RGP fractions were pooled and 
concentrated to ~ 10 mg/ml for crystal trials. For metal-binding assays, a procedure similar to that 
performed on OsUAM1 was adopted; all AtRGPs were treated with EDTA to remove bound metal, 
and the enzymes were concentrated to ~ 1 mg/ml in 25 mM Bicine pH 8.5. 
 
2.3.4 Over-expression and purification of DrUGM wild-type and mutants 
The gene encoding wild-type DrUGM was cloned into a pHISTEV vector and was 
transformed into E.coli Tuner cells (Novagen, USA).24 The cells were grown overnight at 37 °C 
in a 100 ml LB culture with 100 µg/ml kanamycin. 10 ml of this overnight culture was subcultured 
into 1L culture flasks and grown until an OD600 of 0.6 was reached. Protein over-expression was 
induced with 0.4 mM IPTG, and the cells were cultured at 30 °C for 4-5 hours. The cells were 
stored in -80 °C after harvesting by centrifugation at 4000 rpm and 4 ºC. The frozen cell pellets 
were re-suspended in lysis buffer; 100 mM potassium phosphate pH 8.0, DNase and lysozyme at 
20 µg/ml, 1 mM 4-(2-Aminoethyl) benzene sulfonyl fluoride hydrochloride (AEBSF), 0.1 % 
Triton-X and stirred at 4 °C for 30 minutes. The lysed cells were sonicated for 2 min (10 sec on/off 
pulse) and centrifuged at 15000 rpm for 30 minutes at 4 °C. The supernatant was heat treated for 
10 min at 55 °C, to precipitate contaminating proteins. The suspension was then centrifuged again 
at 15000 rpm for 30 minutes at 4 °C. The sample was dialyzed against 25 mM potassium phosphate 
pH 8.0. After four buffer exchanges, the dialysate was loaded onto an HQ20 anion exchange 
column (Applied Biosystems, USA) pre-equilibrated with 25 mM potassium phosphate pH 8.0. 
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The protein was eluted with 25 mM potassium phosphate pH 8.0 buffer, with a gradient from 0 M 
and 1 M NaCl. Fractions containing the enzymes were pooled together and dialyzed against 50 
mM potassium phosphate pH 8.0. Required amount of solid ammonium sulphate was added to the 
dialyzed protein to make it up to 30 % (w/v) ammonium sulphate. The sample was loaded onto an 
HP-20 hydrophobic interaction column (Applied Biosystems, USA) pre-equilibrated with 50 mM 
potassium phosphate pH 8.0, 30% (w/v) ammonium sulphate. The protein was eluted with 50 mM 
potassium phosphate pH 8.0 using a gradient of 30 - 0% (w/v) ammonium sulphate. The eluted 
protein fractions were dialyzed against 50 mM Bis-tris propane pH 8.0 and concentrated to ~5 
mg/ml, for the next stage. A third purification step was employed, using a gel-filtration column 
(GE Healthcare), pre-equilibrated with 50 mM Bis-tris propane pH 8.0. The protein was loaded 
onto the column, and the enzyme fractions were collected and concentrated to ~ 7.5 mg/ml for use 
in crystal trials. Gel electrophoresis was used to analyze the purity of the sample. The protein was 
flash-frozen in liquid nitrogen and stored as 50 µl aliquots at -80 °C. Stocks were also made to ~ 
1 mg/ml, for use in kinetic assays. All the DrUGM point mutants were also prepared by following 
the same procedure. 
 
2.3.5 Over-expression and purification of MtUGM  
  The gene encoding for MtUGM was cloned into pDEST-HisMBP vector, using Gateway 
cloning technique that was described earlier.72 The plasmid was transformed into BL21 Gold over-
expression cells and confirmed by sequencing (Applied Genomics Center, National Research 
Council, Saskatoon, Canada). A single colony of cells was grown overnight in LB media at 37 °C 
with 100 µg/ml ampicillin. The cells were subcultured into 2 ×1 L LB media cultures, 
supplemented with 100 µg/ml ampicillin and grown until an OD600 of 0.4 - 0.5 was reached. The 
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cells were, induced with 1 mM IPTG (final concentration) and grown overnight at 15 °C. The cells 
were harvested by centrifugation at 3500 rpm and 4 °C for 20 minutes. The cell pellets were re-
suspended in lysis buffer (25 mM Tris pH 7.5, 150 mM sodium chloride and 20 µg/ml of DNase) 
for 30 minutes. Sonication (3 min, 15 sec on/off pulse), and centrifugation (15000 rpm, 30 min at 
4 °C) were performed on the re-suspended cells.  
The supernatant, which was filtered using a 0.2 µM filter, was loaded onto a GE healthcare 
Dextrin Sepharose column, pre-equilibrated with 25 mM Tris pH 7.5, 150 mM NaCl. The column 
was washed with the same buffer, to remove all unbound proteins, and the MtUGM with MBP-tag 
was eluted from the column using 25 mM Tris pH 7.5, 150 mM NaCl and 50 mM maltose. The 
eluted protein was dialyzed against 25 mM Tris pH 7.5, 150 mM NaCl to remove maltose and 
concentrated to ~ 5.5 mg/ml. To cleave the MBP-tag, the concentrated sample was then treated 
with TEV protease in a 1:10 ratio and the reaction was left overnight at 4 °C. The reaction mixture 
was further diluted 10 times, using 25 mM Tris pH 7.5, 150 mM NaCl and loaded onto a Ni2+ 
Sepharose affinity column (GE-Healthcare), pre-equilibrated with the same buffer. The cleaved 
MtUGM was collected in the flow through. The MBP and TEV-protease bound to the column were 
then eluted with 25 mM Tris pH 7.5, 150 mM NaCl and 250 mM imidazole. The purified MtUGM 
was dialyzed against 25 mM Tris pH 7.5, 150 mM NaCl and concentrated to ~ 1 mg/ml and use in 
kinetic assays and inhibition studies.  
 
 
 
 
 
56 
 
2.4 HPLC-based assay for mutases 
2.4.1 Kinetic assays for DrUGM mutants 
  The kinetic assay for the DrUGM mutants was performed using the following procedure.51 
A known concentration of the protein, obtained from purification experiments, was used to react 
with a known concentration of substrate in a reaction buffer and the product was analyzed using a 
High-performance liquid chromatography (HPLC) ( Waters HPLC system, with a Waters 510 
pump connected to Waters 717 plus Autosampler and Waters 2487 Dual λ Absorbance Detector). 
The reaction buffer (500 mM sodium phosphate pH 7.0), double-distilled water (Millipore) and 
the reaction vial were argon-degassed. The reactions were performed by adding the DrUGM 
mutant enzyme (at the desired concentration) into a vial containing 50 mM sodium phosphate pH 
7.0. Final enzyme concentrations in the reaction mixture for each mutant was the minimal 
concentration required to make a complete saturation curve by varying concentrations of the 
substrate. The substrate used was UDP-Galf, and the reaction was monitored for the formation of 
UDP-Galp. The final enzyme concentrations used for the assay are as follows; wild-type - 10 nM, 
N372D - 50 nM, W184A - 50 nM, W184F - 50 nM, H88F - 50 nM, R364A - 50 nM and R364K - 
50 nM. The enzyme added to each reaction mixture was reduced with the addition of 20 mM 
sodium dithionite (final concentration) and left to reduce for 30 sec. The substrate (UDP-Galf) was 
added into the vial next to commence the reaction. Typically the substrate concentration was varied 
between 10 µM to 1.5 mM to obtain a saturation curve. The reaction was quenched by the addition 
of n-butanol at a reaction time that resulted in 30 - 40 % conversion of UDP-Galf to UDP-Galp. 
The aqueous layer was collected and analyzed on a CarboPac PA1 (Dionex Inc) column, 
previously equilibrated with filtered and degassed 200 mM ammonium acetate pH 7.0. The 
formation of product was monitored on a UV-spectrophotometer at 262 nm. A typical HPLC-run 
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shows two prominent peaks, one corresponding to the substrate (UDP-Galf) and the other 
corresponding to the product (UDP-Galp). The area under the peaks was calculated using the 
Millennium software (Version 4.0) and the % conversion of substrate was calculated as follows, 
 
 
Using the % conversion value (calculated by Equation 1) obtained at each substrate concentration; 
the rate of product formation per second was calculated and plotted against substrate concentration, 
to obtain kinetic curves for each of the mutants. As substrate available was limited, reactions at 
each different substrate concentration were performed in duplicates and the data was plotted using 
GraphPad Prism software (GraphPad Software, San Diego, CA).  
 
2.4.2 Kinetic assays for MtUGM  
 Kinetics experiments for MtUGM wild-type enzyme were conducted in a similar manner 
to the method described 2.4.1, with minor changes in the reaction condition. All reactions for the 
assay were performed at 37 °C; a final enzyme concentration of 100 nM and a substrate range 
between 10 - 150 µM were used, to make a saturation curve. 
 
2.4.3 Inhibition assays for MtUGM by MS-208 
 For performing inhibition assays on MtUGM, after the enzyme was reduced with the 
addition of sodium dithionite, the inhibitor MS-208 (stock made at 1mM concentration) was added 
to the reaction mixture at the required concentration and left to incubate at 37 °C for 1 minute. The 
reaction was then carried out with the addition of the substrate, quenched with n-butanol and 
analyzed on HPLC as performed for the other assays (Section 2.4.1). Three different 
% Conversion   = 
Area under UDP-Galp peak 
[Area under UDP-Galf peak + Area under UDP-Galp peak] 
× 100%         (1) 
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concentrations of the inhibitor, 60 µM, 120 µM and 200 µM, were used to obtain kinetic curves. 
The plots of rate vs. substrate concentration were prepared by GraphPad Prism software (GraphPad 
Software, San Diego, CA); SigmaPlot software (SigmaPlot 12.0) was used for global fitting of the 
data obtained for each saturation curve; Dixon and Cornish-Bowden plots were drawn using MS 
Excel, to aid in determining the mode of inhibition.  
 
 2.4.4 Kinetic assays for OsUAM1 and mutants 
The kinetic assays were performed adopting the procedure described earlier for DrUGM 
mutants, with minor changes.18 The OsUAM1 enzymatic assay was carried out by incubating the 
enzyme in 20 mM HEPES buffer pH 6.8, 5 mM MnCl2 at 37 °C for 2 minutes. As with DrUGM, 
the enzyme concentration was chosen so that a complete kinetic curve could be obtained. However, 
no reducing agents were added to the reaction mixture, as UAM does not require to be reduced for 
activity. The reaction was initiated with the addition of the desired concentration of substrate, 
UDP-Araf, and the reaction was left to proceed for the necessary amount of time that gave ~ 30 - 
40 % product conversion. The reaction was quenched with the addition of n-butanol, and the 
aqueous layer was analyzed on a CarboPac PA1 Dionex column, previously equilibrated with 210 
mM ammonium acetate pH 6.0, with the flow rate of 1 ml/min. Formation of the product, UDP-
Arap, was confirmed by monitoring UV vis-spec at 262 nm. The % conversion was calculated 
using equation (1) and the rate vs. UDP-Araf concentration was plotted using GraphPad Prism 
software (GraphPad Software, San Diego, CA). 
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2.4.5 Metal binding assays for OsUAM1 and RGPs       
Samples of OsUAM1 wild-type, H273A and all three AtRGPs, pre-treated with 250 mM 
EDTA, were used for metal binding assays. For all studies performed at varying metal 
concentrations, a final enzyme concentration of 20 nM and final substrate concentration of 10 µM 
were used and the reactions were conducted for 30 seconds. To obtain the Mn2+ metal curve, 
concentrations of MnCl2 were varied between 10 µM to 5 mM. Similarly solutions of ZnCl2, 
CoCl2, CuCl2, MgCl2, and CaCl2 were used to obtain curves for the other divalent metal ions, Zn
2+, 
Co2+, Cu2+, Mg2+ and Ca2+ respectively. Each of the reactions was performed in duplicates, and 
the % conversion values were obtained. The maximum value of % conversion obtained at a 
particular concentration of Mn2+ metal was chosen as 100 % relative activity, and all other values 
were calculated relative to this value for metal-binding assay plots. A similar strategy was followed 
for all other divalent metals. 
 
2.5 Crystal trials for mutases       
2.5.1 DrUGM mutants and wild-type enzyme 
 Microbatch under oil method was used to perform crystal trials on DrUGM mutants and 
wild-type enzyme.73,74 Since wild-type DrUGM and DrUGM N372D were previously co-
crystalized with the substrate UDP-Galp, crystal trials were focused on obtaining co-crystals of 
the five other point mutants with the substrate and the holoenzyme for wild-type DrUGM. The 
concentration of the point mutants used for all the trials was kept at ~ 7.5 mg/ml. The enzyme was 
first reduced by the addition of 20 mM sodium dithionite, the reducing agent, and 15 mM final 
concentration of substrate was added to the sample. To set up crystallization drops, the protein was 
pipetted into wells in a micro batch plate, and the crystallization solution was added in a 1:1 ratio. 
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The drops were covered with paraffin oil quickly and set at room temperature. Commercial screen 
kits (Qiagen), each containing 96 different conditions was used for setting up the micro batch 
plates. Initial crystal hits were obtained across conditions in many screens including, Classics II 
suite, PEGs I and II suites and the PACT suite. A similar approach was adopted for trials carried 
out for the wild-type enzyme without the addition of reducing agent or the substrate. The crystal 
hits, in this case, were obtained with conditions from the Classics II suite. For optimization of the 
hits, grid-screens were set-up around these positive conditions. Grid screens were manually 
prepared by varying the final concentrations of the various components in the crystallization 
solution. In the case of the holoenzyme, additive screens (Qiagen) were also used for further 
optimization. 
Rod-shaped bright yellow crystals were obtained in a week and were let to grow for two 
weeks before harvesting and flash-freezing. 20 % PEG 400 with 80 % crystallization solution was 
used as a cryoprotectant solution for flash-freezing DrUGM crystals in liquid nitrogen. 
 
2.5.2 GaHM crystals with substrate mimics 
 The set-up for obtaining GaHM crystals was similar to that described for DrUGM.73,74 
GaHM was co-crystallized with two different substrate mimics, GDP-mannose, and GDP-glucose. 
Microbatch under oil technique was used, and the protein solution was reduced with sodium 
dithionite (turning the protein colorless), prior to the addition of the substrate mimic, GDP-
mannose. The concentrations of GaHM protein, sodium dithionite, and GDP-mannose were ~ 7.5 
mg/ml, 20 mM and 15 mM respectively. The drops were set-up at 4 °C, in a 1:1 ratio of protein to 
crystallization solutions, and covered with paraffin oil. A few conditions in Classics II, PACT and 
PEG1 screens gave initial hits. A condition from Classics II screen containing, 0.2 M Ammonium 
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sulphate, 0.1 M Bis-Tris pH 6.5 and 25% (w/v) PEG 3350, produced a cluster of needle-like yellow 
crystals that appeared within a week. Grid-screens were set around this condition, and further 
optimization was done by using the additive screens. Crystals were obtained with both the substrate 
mimics and were left to grow for two to three weeks before flash freezing using liquid nitrogen.  
 Two different types of cryoprotectant solutions were made for flash freezing GaHM 
crystals.74 For FADox crystals, 20 % (v/v) of ethylene glycol and 80 % crystallization solution was 
used, while FADred, crystals were initially re-reduced with  the addition of sodium dithionite (final 
concentration in 20 mM) along with 15 mM GDP-mannose in a cryoprotectant solution made of 
20 % ethylene glycol and 80 % crystallization solution. The crystal was then looped out of the 
microbatch plate wells and washed thrice in the cryoprotectant solution, to remove mother liquor, 
and flash-frozen rapidly.  
 
2.5.3 Crystal trials on OsUAM1 and AtRGPs 
 Microbatch under oil and vapour diffusion techniques were both used for crystal trials of 
OsUAM1 and AtRGPs. Crystallization experiments were conducted to co-crystallize these 
enzymes with UDP-Galp, since the actual substrate, UDP-Arap, is not commercially available. All 
the enzymes were dialyzed against a buffer containing, 25 mM Bicine pH 8.5, 2 mM manganese 
chloride and therefore, required only the addition of UDP-Galp to a final concentration of 15 mM 
before setting up the protein drops using crystal screens. Microbatch plates were set up in a 1:1 
ratio, of protein solution and crystallization solution, using commercially available screens 
(Qiagen). A number of grid-screens were set up around positive hits, and additive screens were 
also used, to see if any of these conditions could be optimized, to further improve the quality of 
crystals. OsUAM1, without the His-tag, was also prepared and used for setting up trials to see if 
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the absence of the tag would help in obtaining better quality crystals. Trials were performed at 4 
°C, 15 °C and room temperature. 
Crystal trials, in the case of AtRGPs, were carried out in a similar fashion to that described 
for OsUAM1. Conditions giving microcrystalline materials and spherulites of AtRGP1 were 
further optimized. Grid-screens for optimization were set up using vapour diffusion - Hanging 
drop technique, where the crystallization drop is set to hang over a reservoir containing the 
crystallization solution. The drop was prepared by mixing the protein solution and reservoir 
solution in a 1: 1 ratio set on a thin plate, which is then sealed over the reservoir. The crystalline 
material that appeared within two days in some of the conditions was looped out, washed with 
reservoir solution and crushed using a seed bead, to be utilized as macro-seed-stock for further 
experiments. The seed-stock was further diluted down to different ratios 1: 10, 1:100 and 1:1000 
and used to set up more hanging drop plates. The crystallization drop, which now contains protein 
solution, reservoir solution and seed solution in 1.5:1:0.5 ratio was sealed over the reservoir 
solution. Other drop ratios were also tried to see if the quality of the crystals could be improved. 
 
2.6 Data collection, processing, and refinement of GaHM crystal structures 
GaHM crystals, co-crystallized with substrate mimics GaHMox: GDP-mannose, and 
GaHMred: GDP-mannose were diffracted at the Canadian Light Source (CLS), Saskatoon, Canada. 
Datasets were collected on the 08B1-1 beamline, equipped with MD2 micro diffractometer and a 
Rayonix MX300HE X-ray detector. The crystal to diffractometer distance was set at 280 mm and 
600 images were collected for each dataset with an oscillation of 0.25° and exposure time of 1 sec. 
The data processing and scaling were performed using the Autoprocess pipeline.75,76 
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GaHM crystal structures were solved using the Molecular replacement method with 
MOLREP program within the CCP4 package.77-79 GaHM models available from crystal structures 
of GaHM solved with GDP previously solved by Dr. Sean Darlymple [unpublished results], were 
used for finding a structure solution. All the solutions had 2 copies of the GaHM monomer in an 
asymmetric unit (ASU).80 
 PHENIX was used to refine the structures, using the output model PDB from the CCP4 
package and the corresponding .mtz files for each structure.81,82 Initially, Rigid-body refinement 
was performed to refine the position of the monomers. Non-crystallographic symmetry (NCS) 
restraints were turned on for each refinement run. To remove model bias, simulated annealing was 
performed using Cartesian dynamics at 5000 K. The output models, after each refinement run, 
were re-built in COOT.83 The refinement and rebuilding of each model were performed iteratively 
until satisfactory progress was made with R-work/R-free. Another round of simulated annealing 
was done using Cartesian dynamics; this time, at a lower starting temperature of 2500 K. The 
geometry restraints information of oxidized FAD, reduced FADH and the corresponding ligands 
were generated with eLBOW available within the PHENIX software.84 The refinement was re-run 
after including the PDB coordinates and restraint files for the ligands. The electron density maps 
were examined after each run to manually fix residues and regions that were inconsistent. Water 
molecules were added into the refined model using 'Update water' option in PHENIX when the R-
free value was lower than 30%. The waters were verified once again before a final round of 
refinement was completed. All the figures were made using PYMOL (PyMOL version 1.7.4, 
DeLano Scientific LLC)  
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2.7 Modeling studies  
2.7.1 Modeling of DrUGM mutants 
 DrUGM mutants were modeled using an online software Rosetta-Backrub.85,86 For 
modeling experiments, DrUGM wild-type crystal structure, solved with UDP-Galp (PDB id: 
3HDY), with FADred was the input into the software. The residue to be mutated was chosen from 
the sequence (by the residue number), and the desired mutation was submitted to the program. Up 
to twenty different models were made in each run; the model with the best score was chosen and 
used for further docking studies. 
 
2.7.2 OsUAM1 Modeling 
GalaxyWEB and Iterative threading assembly refinement (I-TASSER) were used to 
generate 3D-models of OsUAM1.87,88 Both these programs generate models based on the input 
protein sequence. Five different models obtained, from both GalaxyWEB and I-TASSER, were 
manually compared based on the residues predicted to form secondary structure regions using 
HHpred. This was done to check the consistency of the predicted models. A comparison of all the 
models was performed using PyMOL software (PyMOL version 1.7.4, DeLano Scientific LLC).  
 
2.7.3 Modeling of loop regions of CjGaHM 
 The crystal structure of GaHM solved with GDP-mannose has little or no electron density 
for the flexible loop regions. Since the crystal structures of both AfUGM and TcUGM were overall 
similar to that of CjGaHM, they were used as templates to model the missing GaHM loop regions. 
The missing loop regions were built into the structure using COOT, based on the CjGaHM 
sequence. 
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2.8 Genetic Optimization for Ligand Docking docking for DrUGM mutants 
 Docking of the substrate (UDP-Galp) into the active site of the DrUGM mutants models 
(generated from Rosetta-Backrub program) was performed using Genetic Optimization for Ligand 
Docking (GOLD) software (version 5.2.2).89-92 For performing the docking runs, protein .pdb files 
and substrate .mol2 files were used. A 6 Å binding site was defined using the UDP-Galp binding 
site from the DrUGM: UDP-Galp crystal structure, as the reference ligand. This strategy also 
generated root-mean-square-deviation (RMSD) numbers that helped determine the average 
deviation of all the docked poses generated for a certain .pdb file from the ensemble. Each run was 
allowed to generate 50 docked poses that were scored with ChemPLP fitness function. The output 
was read through the Hermes visualization software (version 1.6.2). The top scoring poses, for all 
the .pdb files in the ensemble, were exported as .pdb files for viewing through PyMOL (PyMOL 
version 1.7.4, DeLano Scientific LLC). 
  
2.9 Circular dichroism on OsUAM1 wild-type and mutants 
  Circular dichroism (CD) spectra were used to determine the approximate secondary 
structure content of OsUAM1 wild-type and all the four mutants (H273A, D110A, D111A, and 
D112A). The experiments were performed using the Chirascan-plus CD spectrometer (Applied 
Photophysics), at the Protein Characterization and Crystallization Facility (PCCF), College of 
Medicine, University of Saskatchewan. At first, the buffer in which the enzymes were present (25 
mM Bicine pH 8.5, 1 mM Mn2+) was scanned to make a baseline measurement in the wavelength 
range that produced CD spectra of high signal to noise ratio (in this case 210 nm - 280 nm). The 
concentrations of each of the samples were adjusted to maintain a total absorbance under 2.0. All 
experiments were performed in a quartz cuvette with a path length of 0.5 mm (Hellma, Germany).  
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All data was collected in triplicate at 20 ºC. The average CD spectrum for each sample was 
obtained after a baseline correction was performed. The secondary structure content was 
determined using the data analyzing software, CDNN 2.1.  
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Chapter 3: UDP-Galactopyranose Mutase  
3.1 UGM from Deinococcus radiodurans  
EcUGM, KpUGM, and MtUGM have been crystallized without the substrate (unliganded), 
to gain insights into the structural architecture and the UGM - FAD interaction.23,31 In the Sanders 
group, UGM from DrUGM and MtUGM were crystallized with the substrate UDP-Galp.24,32 In 
this thesis, the role of some of the active site residues in binding the substrate were studied, using 
DrUGM as a model system. DrUGM has only 37%, 42% and 39% sequence identity with EcUGM, 
KpUGM, and MtUGM, respectively, but the substrate and FAD binding residues are highly 
conserved across the species.24 Crystals of DrUGM, in complex with UDP-Galp, were produced 
by co-crystallization experiments. The structures of the DrUGM: UDP-Galp complex with 
oxidized and reduced FAD were solved to 2.40 Å and 2.50 Å, respectively.24  
The overall structure and active site of UGM was discussed in detail in Chapter 1. The 
overall structure of DrUGM is no different to the other known bacterial UGM structures, having 
three domains and a flexible loop (Figure 3-1). In brief, Domain 1 binds the cofactor FAD, Domain 
2 has five α-helices and a mobile loop while Domain 3 is made of anti-parallel ß-strands. When 
the substrate approaches the active site, the loop and Domain 2 moves towards the active site and 
the loop closes to completely bury the substrate in the active site. Additionally, all three domains 
have significant roles in interacting with the incoming substrate. The FAD-binding Domain 1 aids 
in positioning the galactose sugar under the isoalloxazine ring of FAD for the nucleophilic attack. 
Domain 2 helps to stack the uridine portion of the substrate and ensures that the substrate is in a 
favorable binding mode while Domain 3 and the loop contribute crucial residues towards 
stabilizing the substrate diphosphate.  
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Figure 3-1: The crystal structure of DrUGM.26  
The domains (Domain 1 - blue, Domain 2- green and Domain 3 - grey) and the mobile loop (red) 
are highlighted. Domain 1 binds the FAD (white stick); the mobile loop is in the closed 
conformation, with UDP-Galp (white stick, Domain 2) in the active site. 
 
3.1.1 Active site residues and interactions 
In the bound state, UDP-Galp is folded into a U-shaped conformation and is completely 
buried in the active site. The substrate binding site of DrUGM: UDP-Galp can be divided into 
three regions; the Uridine-binding region, the Diphosphate-binding region, and the Galp-binding 
region. The uridine-binding region in both the liganded and unliganded structures from other 
bacterial species is not much different.33 Tyr179, Phe176, Tyr180, and Phe175 are important 
residues involved in recognizing and stacking the uridine. The uracil ring is stacked in between 
Tyr179, and Phe176; other residues such as Tyr180, Asn296, and Phe175 form a network of 
hydrogen bonds with O2, O4 and N3 of the uracil ring respectively, as shown in Figure 3-2A. 
Loop 
Domain II:  
-helices 
Domain I:  
FAD-binding 
Domain III:  
-strands 
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W184 is involved in hydrogen bonding the C2 and C3 hydroxyl groups of the ribose (Figure 3-
2A). Also, there is little difference in the uridine-binding region when the crystal structures with 
oxidized and reduced FAD were compared. 
(A)  
(B)  
 
Figure 3-2: Uridine and phosphate binding regions of DrUGM.27 
(A) Uridine-binding region, displaying the substrate uridine and active site residues in purple (B) 
Phosphate binding region showing the substrate diphosphates (orange) and active site residues in 
magenta  
 
Two highly conserved arginine residues, Arg198, and Arg305, play critical roles in 
stabilizing the substrate diphosphate in the Diphosphate-binding region. Arg198 is in the center of 
Tyr179 
Phe176 
Phe175 
Asn296 
Thr180 
Trp184 
Arg198 
Arg305 
Tyr209 
Tyr370 
Tyr335 
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the mobile loop and is solvent exposed in the absence of the ligand. This residue moves into the 
active site to stabilize the α-phosphate by forming ionic interactions. Similarly, the β-phosphate is 
also stabilized by another arginine, Arg305, contributed by Domain 2 (Figure 3-2B). Further 
stabilization of the diphosphates is achieved by hydrogen bonding interactions of the conserved 
residues, Tyr209, Tyr370, and Tyr335.  
One of the conserved features of the DrUGM structure is the binding of the sugar moiety 
below the isoalloxazine ring of FAD. The sugar (Galp) is stabilized by His88, His109, Arg364, 
and Asn372 residues, as shown in Figure 3-3. C3 and C6 hydroxyls of Galp forms hydrogen bonds 
with His88 and His109 respectively. Arg364 interacts with the C2 hydroxyl through a water-
mediated hydrogen bond. Furthermore, the C4 hydroxyl of Galp hydrogen bonds with the O4 of 
FAD. This interaction also serves as one of the features for substrate recognition; UDP-Glup with 
the C4 hydroxyl in equatorial position is not recognized by the enzyme.93,94 
 
 
Figure 3-3: Galp binding region of DrUGM.28  
The active site residues are in (cyan).  
 
Arg364 
Asn372 
His88 
His109 
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Thus, 14 critical active site residues have been identified as interacting with the substrate 
in the DrUGM: UDP-Galp complex. These residues by enabling the positioning of other residues 
that interact with the substrate, work to ensure that substrate binding is in the most productive 
orientation within the active site. Based on the observations from the FADred crystal structures, the 
distance between the C1 of Galp and N5 of FAD is in the range of 2.9 Å to 3.2 Å. In the FADox 
crystal structures, the distance between the C1 anomeric carbon of Galp and N5 of FAD is greater 
than 3.5 Å, thus making the N5 of FAD incapable of carrying out the initial nucleophilic attack on 
the C1 anomeric carbon.24 A table (Table 1-2), for comparison of distances between the N5 of the 
isoalloxazine ring of FAD and the C1 of Galp from oxidized and reduced crystal structure of 
various bacterial UGMs, is shown in Chapter 1. 
 
3.2 Purification of DrUGM wild-type and point mutants 
 The DrUGM point mutants were prepared by Dr. Karunan Partha Sarathy, a previous 
member of the Sanders lab.94 The DrUGM wild-type and its mutants used in this study were 
purified using anion-exchange chromatography, hydrophobic chromatography followed by size 
exclusion chromatography. The sample purity was verified using Sodium dodecyl sulfate – 
polyacrylamide gel electrophoresis (SDS-PAGE) (Figure 3-4). 
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Figure 3-4: SDS-PAGE analysis of concentrated fractions of wild-type DrUGM and point 
mutants.29 
 
3.3 Crystallization of wild-type DrUGM  
The structure of unliganded DrUGM wild-type enzyme has not been reported so far. This 
structure will give insights into the enzyme’s structural similarities or differences with the 
unliganded enzyme from other bacterial species. This will also give us vital information on the 
structural and conformational changes DrUGM has to undergo to bind the substrate. Unliganded 
DrUGM was crystallized in 0.1 M Bis-tris propane pH 6.5, 0.2 M potassium bromide, 20 (w/v) % 
PEG 3350 (Figure 3-5). The crystal condition was further optimized to 0.1 M Bis-tris propane 6.0, 
0.2 M potassium bromide, 20 (w/v) % PEG 3350 using grid-screens. The crystals were further 
improved with an additive, iron (III) hexahydrate, added in a 9:1 ratio to the optimized 
crystallization condition. The crystals, however, did not yield good quality diffraction data, as they 
diffracted to ~ 6 Å at the CLS. 
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Figure 3-5: Optimized crystal condition for wild-type DrUGM (holoenzyme).30 
 
3.4 DrUGM point mutants 
Although the roles of most active site residues in substrate interaction and their importance 
to the DrUGM active site are well understood, the structural roles of a few active site residues, 
such as Trp184, Arg364, Asn372, and His88, in binding the substrate are not clear (Figure 3-6). 
Six point mutants of DrUGM were prepared to study their importance to substrate binding. The 
roles of the residues mentioned above were studied by performing HPLC-based kinetic assays, 
modeling using Rosetta Backrub and GOLD docking studies. First, results from the efforts to 
crystallize these mutants with the substrate are discussed. 
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Figure 3-6: The active site residues of DrUGM highlighting point mutants prepared for 
study.31  
 
3.4.1 Crystallization and diffraction of DrUGM point mutants 
Crystals of the point mutants co-crystallized with UDP-Galp were obtained in the 
following conditions. H88F was crystallized in, 0.1 M Sodium acetate pH 4.6, 25% (w/v) PEG 
4000; R364A in 0.1 M Sodium acetate, pH 4.6, 15% (w/v) PEG 20000; R364K in 0.1 M sodium 
acetate pH 4.6, 4% (w/v) PEG 4000; W184F in 0.2M Sodium iodide 0.1M Bis-Tris propane pH 
6.5, 20% (w/v) PEG 3350 and W184A 0.1 M MES pH 6.5,30% (w/v) PEG 4000, respectively. 
The crystals are shown in Figure 3-7.              
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In general, the DrUGM mutant crystals diffracted poorly; diffraction experiments were 
conducted on a large number of crystals of each mutant at the CLS. However, the best diffraction 
datasets collected were in the 4 - 6 Å range, which was not good enough to observe the mutations 
or changes in substrate binding. Apart from optimizing the crystals by various grid screens or 
additive screens, a number of post-crystallization treatment techniques were also performed. 
Allowing the crystals to anneal for 5-10 seconds before diffraction (performed at CLS); exposing 
them to air for up to 20 minutes before freezing; transferring hanging drops onto crystallization 
solutions having increasingly higher concentrations of various crystallization ingredients (up to 15 
%) over 8 -12 hours.95-97 However, none of these methods seemed to improve diffraction quality 
since the crystals developed cracks or damaged easily. 
    
Figure 3-7: Crystal hits for DrUGM point mutants.32   
(A) H88F, (B) R364A, (C) R364K, (D) W184F and (E) W184A  
 
(A)         (B)            (C) 
(D)      (E)     
0.2M Sodium iodide, 
0.1M Bis Tris propane 
pH 6.5& 20% (w/v)  
PEG 3350 
76 
 
3.4.2 Kinetic evaluation of mutants 
3.4.2.1 W184A and W184F 
The Michaelis-Menten curves for W184A and W184F mutants are shown in Figure 3-8. 
Mutating Trp184 to alanine has a drastic effect on the Km value of DrUGM. The Km increases ~ 
20-fold compared to the wild-type enzyme, which means that the enzyme now requires more 
substrate to achieve half-maximal activity. kcat, the turnover number of the enzyme decreases ~ 
360 times. The Km and kcat values for the W184F mutant are better compared to the alanine mutant, 
although still not as good as the wild-type enzyme. The Km of W184F is 670 µM, which is a ~ 12 
- fold increase in the substrate required to obtain half-maximal activity but the kcat decreases by ~ 
15 times. In addition, the specificity constant (kcat / Km) value is also better for W184F than the 
W184A. The kinetic constants are shown in Table 3-1. 
 
(A)                   (B) 
 
Figure 3-8: Michaelis-Menten curves for (A) W184A and (B) W184F mutants.33  
 
3.4.2.2 R364A and R364K  
Mutating Arg364 to alanine or lysine decreased the Km value of the enzyme by 6- fold and 
22-fold respectively, as shown in Table 3-1. Both these mutants required lesser amounts of 
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substrate to get to half-maximum activity, compared to the wild-type but their kcat values were 
rather insignificant. R364K had only a slightly better kcat than the alanine mutant, even though 
lysine is a positively charged residue. The Michaelis-Menten curves for R364A and R364K are 
shown in Figure 3-9. 
 
(A)              (B) 
 
Figure 3-9: Michaelis-Menten curves for (A) R364A and (B) R364K mutants.34  
 
 
3.4.2.3 H88F  
In DrUGM, His88 interacts with the C3 hydroxyl of the substrate sugar. However, in 
eukaryotic UGMs, this histidine is replaced by phenylalanine. The H88F mutation was made to 
see if there was any observable effect on the active site of bacterial UGMs since phenylalanine 
cannot contribute to coordinating the hydroxyl of the sugar. The kinetic parameters derived from 
the plot (Figure 3-10) show that there is a decrease in the Km by ~ 11-fold, but the kcat is only 4-
fold less (Table 3-1). The turnover number is only 4-fold less than the wild type enzyme, making 
it more efficient as evidenced by the better specificity constant. 
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3.4.2.4 N372D 
 Apart from stabilizing the α-phosphate of the substrate, Arg198 also binds the substrate in 
the active site by hydrogen bonding with Asn372. The N372D mutant was made on the basis that 
in KpUGM, the residue that interacts with arginine is an aspartic acid. Our kinetic evaluation of 
this mutant shows that the kinetic parameters are more similar to that of wild-type KpUGM than 
to wild-type DrUGM, in terms of kcat (Table 3-1).  
 
(A)                  (B) 
 
Figure 3-10: Michaelis-Menten curves for (A) H88F and (B) N372D mutants.35 
 
Table 3-1: Kinetic evaluation of DrUGM active site point mutants.7 
Enzyme Km (µM) kcat (s-1) kcat / Km   (s-1µM-1) 
DrUGM wild type 55 ± 7 66 ± 2 1.18 
W184A 1007 ± 61 0.18 ± 0.01 1.8 × 10-4 
W184F 670 ± 26 4.26 ± 0.08 6.36 × 10-3 
R364A 9 ± 0.3 2.94 × 10-5 3.26 × 10-6 
R364K 2.5 ± 0.6 0.17 ± 5 × 10-3 7.6 × 10-2 
H88F 5.1 ± 0.3 16.1 ± 0.2 3.36 
N372D 54 ± 7 9 ± 0.4 0.17 
KpUGM wild type 45 ± 6 5 ± 0.6 0.11 
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To understand the structural changes caused by these active site mutants and to observe 
possible changes that may affect the substrate binding mode, DrUGM mutant models were built, 
using the modeling program Rosetta-Backrub, and they were compared with the crystal structure 
of the wild-type enzyme. An outline of the method used by this software to perform modeling has 
been included in Supplementary Section S.1. In general, the overall structures of these mutants 
were similar to the wild-type enzyme except for a few residues in close proximity to the mutation.  
 
3.4.3 Results from modeling studies 
3.4.3.1 W184A and W184F 
The structural overlay of the wild-type enzyme on DrUGM W184A shows that the alanine 
is ~ 6 - 7 Å away from the uridine-ribose of UDP-Galp, and unlike the tryptophan, it is not in a 
position to coordinate the C2' and C3' hydroxyls of the ribose (Figure 3-11A). In DrUGM W184F, 
the phenylalanine is also unable to establish contacts with the ribose (Figure 3-11B). However, 
phenylalanine, being a much more bulky group than alanine, contributes in the π-stacking of the 
uridine-ribose. In both these models, Gln183 rotates to help in coordinating the C2' ribose 
hydroxyl. DrUGM W184A shows more changes in the backbone of residues, around the point 
mutation, compared to the DrUGM W184F enzyme.  
  
80 
 
 
(A)  
(B)  
 
Figure 3-11: Models of W184A and W184F as generated by Rosetta Backrub.36 
The wild-type residues are in orange, and the mutant residues for (A) W184A and (B) W184F are 
in green. 
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3.4.3.2 R364A and R364K 
 Arg364 is in a position to coordinate the cofactor FAD and also make water-mediated 
contacts with the C2 hydroxyl of the galactose ring of the substrate. Mutating this arginine to 
alanine removes these interactions (Figure 3-12A). Based on the models generated, the mutation 
may also change the positioning of a few residues in the active site, such as Tyr370 and the critical 
phosphate stabilizing Arg198. These small changes in the active site could affect the substrate 
binding mode. The model generated for R364K is also similar to R364A in that the above-
mentioned residues are positioned differently. However, in this case, Lys364 can either interact 
with FAD or form a water-coordinated hydrogen bond with the C2 substrate hydroxyl due to its 
flexible side chain, since unlike Arg364 it cannot simultaneously make both interactions (Figure 
3-12B).   
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(A)  
(B)  
 
Figure 3-12: Models for R364A and R364K as generated by Rosetta Backrub.37  
The wild-type residues are in orange, and the mutant residues for (A) R364A and (B) R364K are 
in green. 
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3.4.3.3 H88F        
His88 makes hydrogen bonds with the isoalloxazine ring of FAD and the C3 hydroxyl of 
the galactose ring, as shown in Figure 3-13. The model generated for the DrUGM H88F indicates 
that even though phenylalanine is incapable of making contacts similar to those made by histidine, 
its aromatic ring is in a relatively similar position to that of the histidine ring (Figure 3-13). This 
may have some stacking effect on the isoalloxazine ring and galactose sugar, thereby aiding in the 
positioning of the sugar for nucleophilic attack by FAD. 
 
Figure 3-13: Model for H88F as generated by Rosetta Backrub.38  
The wild-type residue His88 is in orange, and the mutant residue Phe88 is in green 
 
3.4.4 Docking of DrUGM mutants 
 UDP-Galp was docked into the active site of the wild-type enzyme and the mutant 
structures, using the ensemble docking feature in GOLD. The process of creating an ensemble in 
UDP-Galp 
Phe88 His88 
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GOLD is described in Supplementary Section S.2. The advantage of this technique is the ability 
to produce poses of the docked substrate for direct comparison of the superimposed structures. 
Each run generates numbers that can be analyzed to yield further information about substrate 
binding in the various mutants, thereby providing information about the effect of the mutation. 
The results shown in this section has been tabulated using four different numbers generated from 
the docking runs. Scores under 'ensemble analysis', explain which protein in the ensemble docks 
the substrate better; generally the higher the score for the protein, the better the substrate docks in 
the protein. Each run is asked to generate 100 poses of the substrate for the ensemble. Proteins 
among the ensemble which provide more favorable interactions for docking of the substrate 
generate a higher number of docked poses. So, the number of poses generated for each protein in 
the ensemble is also tabulated for analysis. Average RMSD of the ranked poses gives an idea of 
how much the atoms of the docked poses have moved with respect to the crystallographic substrate 
binding pose. Finally, the average distance (Å) between N5 of FAD and C1 anomeric carbon of 
the Galp (sugar) is also calculated to analyze how the docked poses compare to the distance 
measured in the crystal structure. This number also gives an idea of how the changes due to 
mutations affect the productive mode of substrate binding in the active site. 
 
3.4.4.1 Trp184 
In general, the docked poses of both mutants (W184A & W184F) are not in the correct 
conformation necessary for the catalysis of the reaction. Since there is no Trp184 to coordinate the 
ribose hydroxyls in both the mutants, most docking poses of the mutants are flexible, especially in 
the uridine-ribose region (Figure 3-14).  
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Figure 3-14: The top GOLD docking poses for W184A and W184F.39  
The top-ranked docking poses from wild-type DrUGM (orange), W184A (yellow) and W184F 
mutants are shown superimposed on the UDP-Galp (stick; white) from the crystal structure. 
 
Table 3-2 lists the scores from ensemble analysis, percent of poses for each structure in the 
ensemble and the average RMSD of the docked poses. The wild-type enzyme accounts for 66 % 
of the docked poses and also has the highest score from this ensemble analysis. W184F has a better 
score and more % poses than W184A. Although W184F has a lower average RMSD of the docked 
poses when compared to W184A, the wild-type enzyme still has the lowest value. 
 
3.4.4.2 Arg364 
The docked poses obtained for R364 mutants are shown in Figure 3-15. Due to the changes 
in conformation of residues such as Arg198, Tyr370, and the mutated residues, the Galp portion 
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of the substrate is observed to have moved further away from its position under the FAD, in the 
docked poses.  
 
Figure 3-15: The top GOLD docking poses for R364A and R364K.40  
The top-ranked GOLD docking poses for wild-type DrUGM (orange), R364A (yellow) and 
R364K (green) mutants shown superimposed on the UDP-Galp (stick: white) from the crystal 
structure 
 
Table 3-3 indicates that the ensemble analysis scores of the mutants are lower than the 
wild-type enzyme, and the lysine mutant is better than the alanine mutant. The % of docked poses 
is much lower, and the average RMSD is higher for the mutants than the wild-type, reflecting the 
inability of the substrate to bind in a productive conformation. However, an overall comparison of 
the two mutants shows that R364K scores better than R364A.  
 
 
  
UDP-Galp 
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Table 3-2: GOLD docking results for Trp184.8 
 
Table 3-3: GOLD docking results for Arg364.9 
Enzyme 
Ensemble 
analysis score 
% Poses 
Average 
RMSD 
Average N5 (FAD) 
C1 distance (Å) 
Wild-Type 18.84 50 1.39 3.63 
R364A 13.61 16 2.43 4.76 
R364K 16.98 34 2.16 4.42 
 
Table 3-4: GOLD docking results for His88.10 
Enzyme 
Ensemble 
analysis score 
% Poses 
Average 
RMSD 
Average N5(FAD) C1 
distance (Å) 
Wild-Type 26.22 48 1.90 4.09 
H88F 26.49 52 1.30 3.67 
 
3.4.4.3 His88 
Ensemble docking scores of H88F are better than the wild-type enzyme. The docked poses 
are also similar to the wild-type enzyme, as shown in Figure 3-16. The % docked poses based on 
the number of solutions in each run, and the average RMSD of docked poses of UDP-Galp is 
slightly better for the mutant, as shown in Table 3-4. This could be due to the hydrophobic Phe88 
being capable of keeping the Galp and the isoalloxazine ring in the correct position without 
significant changes to the backbone of residues nearby.  
Enzyme 
Ensemble 
Analysis score 
% Poses 
Average 
RMSD 
Average N5 (FAD) C1 
distance (Å) 
Wild-Type 24.16 66 1.41 3.50 
W184A 22.84 14 2.00 4.28 
W184F 23.04 20 1.81 4.57 
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Figure 3-16: The top GOLD docking poses for H88F mutant.41  
The top-ranked GOLD docking poses for wild-type DrUGM (orange), H88F mutant shown 
superimposed on the UDP-Galp from the crystal structure 
 
3.4.5 Crystal structure of N372D 
The crystal structure of N372D was solved to 2.7 Å by previous members of the Sanders 
lab.94 The overall structures of the substrate bound DrUGM and that of the N372D mutant are 
similar. In this crystal structure, Asp372 occupies a similar position to Asn372 and can make 
hydrogen-bonding interactions with Arg198. Asp372 is able to make two hydrogen bonds whereas 
Asn372 is able to make only one with Arg198 (Figure 3-17). However, this mutation has little 
effect on the binding mode of the substrate, as the conformations of active site residues do not 
change much when compared to the wild-type enzyme. The FADred crystal structure of wild-type 
His88 
Phe88 
UDP-Galp 
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KpUGM shows that KpUGM Asp351 is in position to form two bonds to stabilize Arg174, the 
residue that moves in with the mobile loop.93 
 
 
Figure 3-17: Arg198 and Asn372 of wild-type DrUGM and N372D mutant.42  
The wild-type residues are shown in orange while those of N372D are shown in green. 
 
3.4.6 Discussion 
Results from kinetic assays, modeling, and docking experiments were analyzed to 
understand the role of the chosen DrUGM active site residues in binding UDP-Galp in an active 
conformation. In the wild-type enzyme, Trp184 interacts with the ribose hydroxyls through 
hydrogen bonds. Both Trp184 mutants are unable to coordinate the ribose, but the presence of the 
bulky, aromatic phenylalanine has an influence on substrate binding, as evidenced by the kinetic 
and docking experiments. The results obtained from docking experiments are comparable to those 
obtained from kinetic assays. The wild-type enzyme has much higher efficiency than the two 
mutants. W184A and W184F have displayed a loss of efficiency and a decreased ability to bind 
UDP-Galp 
Arg198 
Asn372 
Asp372 
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the substrate when evaluated by kinetic assays. This is also reflected in the docking studies as the 
wild-type enzyme has the highest score from ensemble analysis and a higher number of docked 
poses with a lower RMSD. Moreover, the higher average RMSD of the poses generated for the 
mutants suggest that the substrate is mostly not held in the productive conformation within the 
active site; a factor that could be leading to the loss in kinetic efficiency of the mutants. The 
aromatic phenylalanine (W184F) may have a positive effect on substrate binding. The W184F 
mutant has a lower average RMSD for the docked poses and a better kinetic efficiency than the 
W184A mutant. Therefore, even though the wild-type Trp184 can coordinate the ribose hydroxyls, 
the aromatic rings and the hydrophobic nature of this residue are responsible for positioning the 
uridine portion of the substrate via hydrophobic interactions thereby making it an essential residue 
for ensuring the best substrate binding mode.  
Arg364 is the third arginine in the active site, apart from the arginines that stabilize the 
substrate diphosphate. This residue interacts with the FAD in the absence of the substrate in the 
active site but moves into the active site to coordinate the incoming substrate. The models predict 
changes in the active site conformation, as this residue not only influences the positioning of Galp 
but also influences the position of residues crucial for stabilizing the substrate diphosphate. The 
possible movement of Tyr370 towards the β-phosphate of the substrate is likely to displace the 
critical residue Arg198 from its position, thereby causing changes to the substrate binding mode. 
The docked poses have the diphosphate moiety of the substrate occupying a different position in 
the active site and Galp is away from the isoalloxazine ring, compared to the wild-type enzyme. 
The average distance between the N5 (FAD) of C1 anomeric carbon (Galp) is close to 4.5 Å (and 
higher than wild-type) for the mutants. This trend is also reflected by the kinetic assays performed 
with the mutants. R364A and R364K were unable to bind enough substrate to achieve the half-
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maximal activity of the wild-type and had very low efficiency. This could be due to the inability 
of both mutants to bind the substrate in a productive conformation within the active site, as 
suggested by the docking studies. Ensemble analysis scores both mutants lower than the wild-type 
enzyme, and R364K better than R364A. Therefore, apart from making contacts with FAD, Arg364 
helps keep critical residues like Arg198 in the correct position, thereby letting the substrate bind 
in the most productive mode.  
The mutation of His88 with Phe88 was done based on eukaryotic UGM sequences. As 
evidenced by the kinetic studies, the mutant enzyme is able to bind the substrate in the productive 
binding mode. The docking experiments are also in favor of this argument. The docked poses of 
the substrate in the mutant are similar to that of the wild-type enzyme. Moreover, ensemble 
docking scores H88F marginally better than the wild-type enzyme and the average RMSD of 
docked poses of UDP-Galp is also better for the mutant. DrUGM H88F thus aids in positioning 
the sugar under FAD, due to the aromatic group of phenylalanine. It is also noted that Phe88 in the 
mutant model occupies a similar position with respect to both the FAD and Galp as that of Phe66 
in the crystal structure of FADred eukaryotic AfUGM.
35 AfUGM Phe66 however, is closer to Galp 
(~ 3.8 Å) than DrUGM His88 (~ 4.2 Å), as it cannot form any bonds with either FAD or Galp. 
Thus, the aromatic imidazole ring of His88 also contributes to positioning Galp, serving to orient 
the sugar for catalysis.  
Once the substrate is in the active site, Asn372 hydrogen bonds with Arg198, thereby 
keeping the mobile loop closed and completely burying the substrate in the active site. The 
DrUGM N372D mutant is able to form this interaction like the wild-type enzyme, without changes 
to the orientation of the substrate or other active site residues. However kinetic studies show that 
the mutation alters the efficiency of the enzyme, making N372D more similar to KpUGM. This 
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may be a result of the two hydrogen bonds that Asp372 can make with Arg198, which may slow 
the release of the product formed, ultimately reducing the efficiency of the enzyme. 
 
3.5 Inhibition of MtUGM by MS-208 
Since UGM is a potential drug target, as mentioned in the introductory chapter, a constant 
search for identification of new lead compounds is underway, and a number of studies have been 
conducted for characterization and analysis of these inhibitors. Inhibitors identified through virtual 
screening have had more success; although in general have low potency against bacterial UGMs. 
Among the non-substrate like inhibitors identified from virtual screening, compounds with a 5-
hydroxy-pyrozole core were generally more successful in inhibiting UGMs and more importantly 
were nontoxic to human cells.54 This section of the chapter will discuss the inhibition experiments 
performed on MtUGM with a recently identified fungicidal compound, MS-208, having the 5-
hydroxy-pyrozole core. Studies described here are focused towards inhibiting prokaryotic 
MtUGM, since it is a validated drug target.21 MS-208 demonstrates moderate inhibition against 
MtUGM (IC50 value ~ 64 ± 1 µM). A study conducted by Dr. Pinto's group (Simon Fraser 
University, British Columbia), hypothesized that MS-208 (Figure 3-18A) may inhibit MtUGM by 
binding to a novel allosteric site. Based on their molecular dynamics, docking and Saturation 
transfer difference-nuclear magnetic resonance (STD-NMR) studies, the allosteric site was 
proposed to be located behind the adenine binding region of FAD [unpublished results].98 This 
proposed allosteric site has a small loop with negatively charged residues, called the A-loop and 
another groove, in between which MS-208 binds, as shown in Figure 3-18B.  
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Figure 3-18: MS-208 and its binding to an allosteric site in MtUGM.43  
(A) The structure of MS-208. (B) MS-208 bound to the allosteric site of MtUGM. The active site 
mobile loop is open since there is no substrate in the active site. (C) The allosteric site (cyan) when 
there is substrate in the active site (cyan). (D) Changes in the binding modes of MS-208 (magenta) 
and A-loop (magenta), when the substrate binds in the active site after MS-208 binds in the 
allosteric site; the destabilized A-loop of the allosteric site (yellow) when MS-208 (yellow) binds 
in the allosteric site in the presence of substrate in the active site [unpublished results].98 
 
UDP-Galp 
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Some of the other significant findings from the study were that MS-208 had a higher 
affinity to MtUGM than the MtUGM: UDP-Galp complex. The binding of MS-208 weakens the 
binding of substrate in the active site due to the inability of the active site residues to be in the right 
conformation. Furthermore, the binding of the substrate also weakens the binding of MS-208 in 
the allosteric site, because of the destabilization of the A-loop (Figure 3-18D). To determine the 
mode of inhibition and to generate kinetic numbers, we kinetically evaluated the inhibition of 
MtUGM by MS-208.  
 
3.5.1 Purification of MtUGM 
To overcome the solubility issues, MtUGM was cloned into pDESTHisMBP, using 
Gateway cloning, so that the protein would be expressed with an N-terminal His-MBP-tag.72 The 
HisMBP-tagged MtUGM was purified by affinity chromatography and the tag was cleaved using 
TEV protease. Pure MtUGM was obtained after applying the sample through a Ni-sepharose 
affinity column.32 The purity of the protein was assessed using SDS-PAGE (Figure 3-19).  
 
Figure 3-19: SDS-PAGE analysis of purified fractions of MtUGM, after the HISMBP-tag 
was cleaved using TEV protease.44 
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3.5.2 Kinetic evaluation of MtUGM inhibition by MS-208  
 The kinetic evaluation of MtUGM inhibition by MS-208 was performed using HPLC - 
based kinetic assays, as described in chapter 2. The enzyme taken in buffer (both at constant final 
concentration) was reduced and incubated with MS-208, reacted with the substrate, quenched and 
analyzed by HPLC to observe product conversion. The final % conversion values were obtained, 
and rates were determined. Three different inhibitor concentrations (60 µM, 120 µM, and 200 µM) 
were used for this study. 
 
3.5.2.1 Michaelis-Menten plot  
Non-linear regression analysis was performed to determine the kinetic parameters. The Km 
and kcat values calculated for MtUGM in the absence of inhibitor were 45.4 ± 3.0 µM and 7.8 ± 0.2 
sec-1, respectively. The Michaelis-Menten plot obtained with and without inhibitor is shown in 
Figure 3-20. At increasing inhibitor concentrations, the Km of the enzyme increases while the 
maximum velocity obtained decreases, as shown in Table 3-5.                   
 
 
Figure 3-20: Michaelis-Menten plot for inhibition of MtUGM by MS-208.45  
The plot displays the Rate vs. Substrate (UDP-Galf) concentrations in the absence of MS-208 and 
the presence of inhibitor at three different concentrations, 60 µM (blue), 120 µM and 200 µM 
(black)  
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Table 3-5: Decreasing values of the apparent Km and maximum velocity (Vmax) of MtUGM 
with increasing MS-208 concentrations.11                
I (µM) Km,app (µM) Vmax,app (µM/S) 
0 45.4 ± 3.0 0.78 ± 0.02 
60 51.5 ± 4.0 0.67 ± 0.02 
120 63.3 ± 6.2 0.63 ± 0.03 
200 90.6 ± 12.4 0.57 ± 0.04 
 
3.5.2.2 Lineweaver-Burk plot  
Initial efforts to globally fit the data points to an equation for competitive inhibition, using 
SigmaPlot, failed, as MS-208 did not behave as a competitive inhibitor. Moreover, competitive 
inhibition was ruled out, since lines corresponding to different inhibitor concentrations did not 
intersect on the y-axis of the Lineweaver-Burk plot, as shown in Figure 3-21. 
 
Figure 3-21: Lineweaver-Burk plot for inhibition of MtUGM by MS-208.46  
This plot shows 1/Rate vs. 1/UDP-Galf, in the absence of MS-208 and the presence of MS-208 at 
three different concentrations, 60 µM (blue), 120 µM and 200 µM (black). 
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The Lineweaver-Burk plot shown in Figure 3-21 was obtained by global fitting of the data 
to the following linear mixed-type inhibitor equation, 
                           
1
V
=
Km
Vmax
 (1 +
[I]
Ki
) (
1
[S]
) +  
1
Vmax
 (1 +  
[I]
α Ki
)                          (2) 
where, Vmax is the maximum velocity obtained for each curve at different inhibitor concentration, 
Km is the Michaelis-Menten constant, S is substrate concentration, I is the inhibitor concentration. 
The values generated for both dissociation constants Ki, Ki', and α, from global fitting of the data 
were 0.13 ± 0.02 mM, 0.4 ± 0.07 mM and 2.99 respectively.  
 
3.5.2.3 Diagnostic Dixon and Cornish-Bowden plots  
Dixon and Cornish-Bowden plots were used to confirm that MS-208 is a mixed-type 
inhibitor of MtUGM. In the Dixon plot, the lines intersected above the x-axis while in the Cornish-
Bowden plot the lines intersected below the x-axis. Hence, the two diagnostic plots taken together 
are indicative of mixed-type inhibition.99 Furthermore, these plots also allow the determination of 
Ki and Ki' values. The Ki value as determined from the Dixon plot shown in Figure 3-22A was ~ 
135 µM. The Ki' value as calculated from the Cornish-Bowden plot shown in Figure 3-22B was ~ 
400 µM. These values are in close agreement with the values calculated from the SigmaPlot global 
fitting.     
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(A)  
(B)  
Figure 3-22: Dixon and Cornish-Bowden plots for inhibition of MtUGM by MS-208.47  
(A) Dixon plot, showing 1/ Rate vs. Inhibitor (MS-208), for various concentrations of UDP-Galf. 
(B) Cornish-Bowden plot, showing UDP-Galf / Rate vs. Inhibitor (MS-208), for different 
concentrations of UDP-Galf.  
 
3.5.3 Discussion 
 The Michaelis-Menten plot displays decreasing Vmax values with increasing inhibitor 
concentrations. In the Lineweaver-Burk plot, the lines drawn at various inhibitor concentrations 
are not intersecting on the y-axis. This suggests that MS-208 is not a competitive inhibitor. The 
best global fit to the experimental data was obtained with an equation for linear mixed-type 
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inhibition, using SigmaPlot. Diagnostic Dixon and Cornish-Bowden plots helped further the 
understanding of the mode of inhibition of MtUGM by MS-208. The lines corresponding to various 
substrate concentrations intersect at a point above the x-axis (second quadrant) in the Dixon plot 
and below the x-axis (third quadrant) in the Cornish-Bowden plot, thus confirming that MS-208 is 
a mixed-type inhibitor.  
                                 
Figure 3-23: General reaction scheme for a mixed-type inhibitor.48 
Furthermore, these complementary plots also helped determine the Ki and Ki' values. The 
Ki and Ki' values obtained from these plots were ~ 135 µM and ~ 400 µM respectively. In this 
case, Ki, the dissociation constant of the EI complex is less than Ki', the dissociation constant of 
the ESI complex, meaning that MS-208 binds more tightly to MtUGM alone than the MtUGM: 
UDP-Galp complex (Figure 3-23). These values are in close agreement with those calculated from 
the global data fit generated using the linear mixed-type inhibitor equation in SigmaPlot. Thus 
based on the observations from the plots it was concluded that MS-208 works as a mixed inhibitor 
of MtUGM. Further experiments will be conducted to prove its binding to the suggested allosteric 
site. Furthermore, improving the inhibition by modifying the structure of MS-208, will also be 
considered. Some of the suggestions will be discussed in Chapter 6.  
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Chapter 4: UDP-arabinopyranose mutase  
Not much information is available about the 3D structure and catalytic mechanism of plant 
UAMs. UAM from rice seed extracts, purified by Konishi et al. (2007), did not have the 
characteristic flavin UV-absorption peak at 450 nm. Furthermore, it was observed that OsUAMs 
were active when tested with divalent metal ions; 5 mM manganese chloride (MnCl2) gave the 
best % activity.18,100 All three AtRGPs were also tested with 5mM MnCl2 for mutase activity, using 
experimental conditions previously developed by Konishi et al.66 
The structural information known about UAM is based on the experimental results and 
hypothesis generated to describe the possible roles of a few residues. Arg158 was believed to be 
the site of glycosylation of OsUAM1. Konishi et al. (2010) explained this based on their 
observations from experiments conducted using 13C-labelled UDP-glucose to glycosylate this 
arginine and then analyzing the trypsin digested glycopeptide fragments by Liquid 
Chromatography-Mass Spectrometry (LC-MS). The alanine mutants of glycosylating arginines 
from OsUAM1 and OsUAM3 (R158A and R156A) exhibited poor or no activity. Moreover, other 
arginines that are in proximity to the site of glycosylation (OsUAM1 Arg165 and OsUAM3 
Arg163) were also proved to be essential for activity. Both, removing only the guanidino nitrogen 
group of OsUAM1 (Arg165 mutating it to a lysine) or removing the side chain completely (Arg165 
mutation to alanine) reduced mutase activity by ~ 12 and ~ 17-fold respectively.101 Similarly, 
mutating OsUAM3 Arg163 to alanine (R163A) had a disastrous effect on activity (~ 50-fold 
reduction in activity). The sequence of rice OsUAMs and AtRGPs have a highly conserved DXD-
motif, characteristic of the glycosyltransferase family. This motif is hypothesized to be involved 
in binding the metal ion, which is necessary for activity. 
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 In the research undertaken on UAM, as a part of this thesis work, the divalent metal ion 
dependency of four chosen UAMs (OsUAM1, AtRGP1, AtRGP2, and AtRGP3) was investigated, 
and a comparative analysis was performed. So far, the role of the metal ion in binding the substrate 
and how the metal ion binds to the active site of the enzyme has not been explored in any of the 
plant UAMs. Hence, experiments were conducted to pick out the enzyme's metal binding region 
and determine the residues that may bind the metal ion in the enzyme's active site through SDM. 
On the basis of these experiments, a possible role for the metal ion in interacting with the substrate 
(UDP-Arap) is also proposed.  
 
4.1 Purification of OsUAM1 and mutants 
 OsUAM1 wild-type and its mutants (H273A, D110A, D111A, and D112A) required for 
this study were cloned into a pEHISTEV vector and transformed into E. coli strain BL-21 gold 
cells. All proteins over-expressed with the N-terminal histidine tag and were purified using nickel 
affinity chromatography. Figure 4-1A shows that the fractions (5-9) contain wild-type OsUAM1 
purified along with other contaminating proteins. The fractions were concentrated and run on a 
Gel-filtration chromatography, to further purify OsUAM1, by removing other contaminating 
bands. The sample purity was analyzed using SDS-PAGE, and it is shown in Figure 4-1B.  
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       (A)                            (B) 
 
 
 
 
 
 
 
 
(A)                  (B) 
 
Figure 4-1: SDS-PAGE analysis after OsUAM1 purification.49  
(A) Gel obtained after Nickel affinity chromatography (B) After further purification using Gel-
filtration chromatography. 
 
4.2 Purification of AtRGPs 
 AtRGPs cloned into pEHISTEV vector and transformed into E.coli BL-21 gold cells were 
unable to successfully over-express a desirable amount of soluble protein. Therefore, AtRGPs were 
cloned into pDESTHisMBP, using Gateway cloning technology. The required protein could be 
expressed with an N-terminal His-MBP-tag, which was cleaved using TEV-protease, due to a 
recognition site inserted after the His-MBP tag. Pure AtRGPs were obtained in the flow-through, 
after applying the TEV-Protease treated sample onto a Ni-sepharose affinity column. The purity 
of the protein was assessed using SDS-PAGE. The gels obtained with AtRGP1 are shown as an 
example in Figure 4-2. 
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(A)              (B) 
 
Figure 4-2: SDSPAGE analysis after AtRGP1 purification.50   
(A) SDS-gel of AtRGP1 purification after Nickel affinity chromatography column (B) After 
cleavage of the His-MBP tag with TEV protease. 
 
4.3 Metal-binding studies on OsUAM1 and AtRGPs  
According to a previous study conducted by Konishi et al. (2007), rice mutase was 
activated in the presence of divalent ions (as shown in Figure 4-3). They observed enzyme activity 
when no divalent metal ions were added to their assay. The value obtained was approximated as 
100% relative activity. Based on this approximation, they discovered that rice mutase activity 
almost doubled in the presence of 5 mM MnCl2, but the same concentration of other divalent 
cations such as MgCl2 and ZnCl2 displayed no significant increase in activity. Other divalent metal 
solutions such as CaCl2, CuSO4, and CoCl2 had an adverse effect on relative activity (decreased % 
relative activity from that obtained with no metal), as shown in Figure 4-3. 
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Figure 4-3: Percent relative activity of UAM with divalent metal ions as studied by Konishi 
et al. (2007).*51 
*Permission to reuse figure attached at the end of this thesis. 
4.3.1 Percent activity of OsUAM1 with varying concentrations of divalent metal ions  
The results obtained here are from reactions performed with constant amounts of substrate 
and enzyme concentrations, and a manganese concentration ranged from 0 to 5 mM. The results 
showed that 5 mM Mn2+ had an inhibitory effect on enzyme activity and the activity increased 
with a decrease in Mn2+ concentration. The % relative activity obtained at 80 µM concentration of 
Mn2+ was much higher, almost double compared to the activity of the enzyme observed at 5 mM 
Mn2+. There was an increase in activity observed from 0 µM (11 %) to 80 µM (100 %) Mn2+ and 
85 - 100 % relative activity was achieved with a Mn2+ concentration between 40 -200 µM (Figure 
4-4A). Excess Mn2+ ion concentration, greater than 320 µM, displayed an inhibitory effect on 
OsUAM1 activity. A second plot obtained with OsUAM1 pre-treated with EDTA to remove 
residual metal, also showed a similar trend (Figure 4-4B). No activity was observed at 0 µM Mn2+, 
which demonstrates that the enzyme is inactive in the absence of any divalent metal ion. Therefore, 
Mn2+ is essential for OsUAM1 activity and is not an activator of the enzyme, as previously stated 
by Konishi et al. (2007). 
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(A)  
(B)  
 
Figure 4-4: Plots showing the change in % Relative activity with Manganese concentration 
of OsUAM1.52  
(A) Percent relative activity vs. Manganese concentration up to 5 mM of OsUAM1 (B) Percent 
relative activity vs. Manganese concentration up to 320 µM of OsUAM1 samples pre-treated with 
EDTA. 
 
4.3.2 Percent activity of OsUAM1 with other divalent metals  
 Other divalent metals such as Mg2+, Zn2+, Co2+, Ca2+, and Cu2+ were used to study the % 
activity of OsUAM1. This was done to understand the effect of these metal ions on mutase activity 
and to make comparisons with the data obtained by Konishi et al. (Figure 4-5).  
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Figure 4-5: Percent activity of OsUAM1, in the presence of other divalent metal ions.53   
(A) The percent relative activity of OsUAM1, in the presence of other divalent metal ions at 80 
µM concentration in the reaction mixture (B) Percent relative activity of OsUAM1with divalent 
metal ions in the range 0 - 320 µM. 
 
It was observed that Zn2+ and Co2+ ions were able to show significantly lower % relative 
activity (close to 70 % for Zn2+ and 60% for Co2+) compared to the % activity obtained with Mn2+ 
at 80 µM concentration (Figure 4-5A). However at 5 mM, they had displayed a very low or no 
effect on activity. Moreover, other divalent metals such as Mg2+, Ca2+ and Cu2+ displayed low 
activity, less than 10% increase in activity at 80 µM.                        
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Another plot was constructed by varying the divalent metal concentrations between 0 µM 
and 320 µM, to see if a trend similar to that of Mn2+ was displayed, using OsUAM1 pre-treated 
with EDTA. It was observed that Zn2+ and Co2+ followed a similar trend with % relative activity 
increasing to a maximum at 80 µM metal concentration and decreasing as metal ion concentration 
was increased to ~ 300 µM or higher (Figure 4-5B). There was no significant rise in activity in the 
case of other divalent metals like Mg2+, Cu2+, and Ca2+. The % relative activity of OsUAM1 
remained less than 10% with all the three divalent metal ions at various concentrations, compared 
to the values obtained with Zn2+ and Co2+.  
4.3.3 Metal binding studies on Reversibly Glycosylated Protein 1  
 A similar trend of lower % activity with higher concentrations of Mn2+ was also noted with 
AtRGP1. However, in this case, maximum % activity was obtained at 40 µM concentration of 
Mn2+ (Figure 4-6A & B). Other trends were more similar to what was already observed with 
OsUAM1. At 40 µM, Zn2+ and Co2+ produced slightly greater than 60% activity (Figure 4-6B). 
The other divalent ions showed lower activity at this concentration and negligible % activity at 
concentrations between 0 and 320 µM. As already described with Mn2+, AtRGP1 displayed a 
decrease in activity at concentrations higher than 40 µM with Zn2+ and Co2+ (Figure 4-6C). 
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(A)  
(B)  
                        (C)    
 
Figure 4-6: Metal binding studies on AtRGP1.54  
(A) Percent relative activity vs. Manganese concentration up to 5 mM (B) Percent relative activity 
of AtRGP1, with other divalent metal ions at 40 µM in the reaction mixture (C) Percent relative 
activity of AtRGP1with divalent metal ions with concentrations ranging from 0 - 320 µM. 
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4.3.4 Reversibly Glycosylated Proteins 2 and 3 (AtRGP2 and AtRGP3) 
AtRGP2 and AtRGP3 both showed similar trends with Mn2+ and other divalent metal ions. 
In the case of AtRGP2, the maximum activity was observed at 40 µM (Figure 4-7A & B); Zn2+ 
and Co2+ were the other two divalent metal ions that displayed 60 % activity at 40 µM (Figure 4-
7B). Though unlike the trend seen thus far, at this concentration, Co2+ had a slightly higher activity 
(3-5 %) than Zn2+. Trends with other divalent ions were similar to AtRGP1 and OsUAM1 from 
concentrations between 0 - 320 µM (Mg2+, Cu2+, and Ca2+ had negligible % activity in this 
concentration range). (Figure 4-7C). 
The graphs for AtRGP3 are shown in Figure 4-8. Here again, Mn2+ displayed the best % 
activity at 40 µM (Figure 4-8A and B), while divalent ions such as Zn2+ and Co2+ displayed the 
next best activity, as seen with AtRGP1 (Figure 4-8B). In the case of AtRGP3, there were no 
aberrations in the trend already established by the other mutases in this study. 
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(A)  
(B)  
                         (C)  
 
Figure 4-7: Metal binding studies on AtRGP2.55   
(A) Percent relative activity of AtRGP2 vs. Manganese concentration up to 5 mM (B) Percent 
relative activity of AtRGP2, with other divalent metal ions at 40 µM in the reaction mixture (C) 
Percent relative activity of AtRGP2 with divalent metal ions in the range, 0 - 320 µM. 
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      (B)  
               (C)  
 
Figure 4-8: Metal binding studies on AtRGP3.56 
(A) Percent relative activity of AtRGP3 vs. Manganese concentration up to 5 mM (B) Percent 
relative activity of AtRGP3, with other divalent metal ions at 40 µM in the reaction mixture (C) 
Percent relative activity of AtRGP3 with divalent metal ions in 0 - 320 µM range. 
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4.4 UAM crystal trials 
Crystallization experiments were conducted with OsUAM1 and AtRGP1 to obtain 
structural information. The results from crystal screening of both these enzymes will be discussed 
here. Purified OsUAM1, concentrated to ~ 6.5 mg/ml in 25 mM Bicine pH 8.5 and 1 mM 
Manganese chloride, was used to set up crystal trials with UDP-Galp (due to commercial 
unavailability of the actual substrate UDP-Arap). For the initial trials, commercially available 
crystal screens were used to set up microbatch plates at room temperature and 4 °C. Most of the 
hits obtained were either spherulites or microcrystalline material; none of the conditions produced 
single crystals. The spherulites were obtained overnight in multiple conditions with the 2-methyl 
2-pentanediol (MPD) screen having 30 - 40% (v/v) MPD concentration in two different buffers; 
HEPES buffer pH 7.0 and Tris buffer pH 8.0 (Figure 4-9A and B). However, the best hits were 
observed within three to four days in the PACT screen conditions #2-6, which had thin clusters of 
needles growing from the initially formed spherulites (Figure 4-9C). These conditions had 0.1 M 
SPG buffer (having succinic acid: sodium dihydrogen phosphate: glycine in a 2:7:7 molar ratios), 
pH 5.0, 6.0, 7.0, 8.0 and 9.0, respectively, and 25 (v/v) polyethylene glycol (PEG) 1500.  
The conditions were further optimized with the use of grid screens while varying the pH 
between 4.0 and 9.0 and the PEG 1500 concentration between 5 and 40 % (v/v). The optimization 
grid screens were performed with both microbatch and hanging drop vapour diffusion techniques. 
Also, additive screen, having 96 different ingredients (containing different anions, cations, and 
detergents) was used. For performing the additive screen, the 96 different ingredients were mixed 
with the PACT screen conditions #2-6, in a 9:1 ratio, (to make 96 different crystallization 
conditions), before setting up the microbatch plate. The experiments were also repeated at various 
temperatures, to see if the changes in conditions would increase the likelihood of obtaining 
113 
 
crystals. Most of the results observed did not give single crystals nor did they improve the quality 
of crystalline material significantly. A grid screen and additive optimization were also performed 
on the spherulites obtained in the MPD screen. Yet again, only spherulites could be reproduced 
with 15-25% (v/v) MPD, with 50 mM potassium iodide and HEPES buffer pH 7.5, using both 
microbatch and vapor diffusion techniques. 
(A)  (B)  
(C)  (D)  
(E)  (F)  (G)  
 
Figure 4-9: Microcrystalline hits observed for OsUAM1 crystal screens.57   
(A) Microcrystalline material observed in the MPD screen for OsUAM1 (B) Spherulites of 
OsUAM1 which take up the Izit dye (C) OsUAM1 microcrystalline material obtained from 
hanging drops containing 20% (v/v) MPD, potassium iodide and HEPES buffer pH 7.5 (D) Small 
crystals obtained from seeding experiments (E) AtRGP1 needle cluster from PACT screen # 6 (F) 
AtRGP1 crystalline material obtained from microseeding in the same condition (G) AtRGP1, plate-
like clusters from microseeding. 
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Seeding techniques were also used to improve crystal quality. The needle clusters, obtained 
from the PACT screen were used in performing both microseeding (including streaking) and 
macroseeding. The crystallization drops were set up using the hanging drop technique and the 
drops were streaked or macroseeded after sufficient equilibration time (3-4 hours). Small tiny 
crystals could be obtained within a day, but they did not grow any further to form larger single 
crystals (Figure 4-9D). 
AtRGP1 was purified and concentrated to ~ 7.0 mg/ml in 25 mM Bicine pH 8.5 and 1 mM 
manganese chloride. Co-crystallization trials of AtRGP1 conducted with UDP-Galp produced 
initial hits in the same conditions (PACT screen conditions #2 - 6), as that of OsUAM1 (Figure 4-
10E). The needle clusters obtained in this case were slightly longer than those obtained with 
OsUAM1. Grid screens were set up around the condition for optimization. Additive screens and 
detergent screens were also performed. Hanging drops were also set to see if the needle clusters 
were reproducible. Seeding experiments were also carried out with this enzyme, using the 
microseeding technique described in Chapter 2. Generally, the seeding trials yielded slightly better 
crystals. In some cases, clustered plate-like crystals were also identified. The best results were thin 
plates in 0.1 M SPG buffer pH 7.0 and 15% (v/v) PEG 1500 (Figure 4-9F & G). The plates were 
tested for quality; however diffraction results yielded very low resolution. 
 
4.5 Results from modeling studies  
Since diffraction quality single crystals of UAM proved to be a difficult task to accomplish, 
modeling studies were performed to gain some insights into the active site residues involved in 
substrate and metal binding. There were no known 3D structures for any of the plant UAM or any 
other proteins with a modest sequence identity (30 - 40 % sequence identity) to UAM, reported in 
115 
 
the literature. Hence, models had to be generated based on the protein sequence of the enzyme. A 
sequence alignment performed on all four sequences (OsUAM1, AtRGP1, AtRGP2 & AtRGP3) 
showed that all the sequences had greater than 85% identity (Figure 4-10B). Therefore, OsUAM1 
was chosen for modeling studies.  
Two different structure prediction (modeling) programs I-TASSER, and GalaxyWEB were 
used to predict a model for OsUAM1.87,88,102,103 A description of the strategy utilized by these 
modeling softwares to predict the model has been included in the Supplementary section S.4. Both 
these programs produced five structural models for the OsUAM1 sequence. Models obtained from 
these online modeling programs, were manually compared against each other (uploading PDB 
coordinates generated in PyMOL) to determine similarities in regions predicted to form secondary 
structures (Figure 4-10A), and also to make an overall comparison of the 3D structure. The 
comparative analysis of each of the five models, predicted by the programs, showed that regions 
of the OsUAM1 sequence picked to form α-helices and ß-strands were consistent overall. The 
regions picked to form loops were often slightly different among the models, but generally 
consistent. The predicted models were also compared to analyze differences in the overall 
structural architecture. The most consistent models generated by both these programs with minimal 
overall differences in secondary structural and 3D architecture were selected and are shown in 
Figure 4-11A & B.  
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(A)  
MAGTVTVPSASVPSTPLLKDELDIVIPTIRNLDFLEMWRPFFQPYHLIIVQDGDPTKTIR  60            
VPEGFDYELYNRNDINRILGPKASCISFKDSACRCFGYMVSKKKYVFTIDDDCFVAKDPS   120   
GKDINALEQHIKNLLSPSTPFFFNTLYDPYREGADFVRGYPFSLREGAKTAVSHGLWLNI 180    
PDYDAPTQMVKPRERNSRYVDAVMTVPKGTLFPMCGMNLAFDRDLIGPAMYFGLMGDGQP 240    
IGRYDDMWAGWCMKVICDHLSLGVKTGLPYIWHSKASNPFVNLKKEYKGIFWQKDIIPFFQN 302     
ATIPKECDTVQKCYLSLAEQVREKLGKIDPYFVKLADAMVTWIEAWDELNPSTAAVENGKAK 364 
 
(B) 
 
 
Figure 4-10: High sequence identity between OsUAM1 and AtRGPs.58  
(A) OsUAM1 sequence showing regions predicted to form helices (in red), β-strands (in blue) and 
coils (in black), as predicted by PredictProtien software. (B) Sequence alignment of OsUAM1 
(UAM) & AtRGP sequences (RGP1, RGP2 & RGP3). The sequence alignment was performed 
using ESPript (Version 3.0) 
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Further analysis of the OsUAM1 model revealed information about the Structural 
Classification of Proteins (SCOP) that UAM may fall under. UAM was predicted to belong to the 
class Alpha and beta proteins (a/b). Among the proteins classified under this category, UAM 
comes under the nucleotide-diphospho sugar transferases fold and superfamily of proteins. The 
commonly observed prominent features of the secondary structural elements of a protein structure 
that belong to this fold are, the presence of a β-sheet layer, sandwiched between two layers of α-
helices (Figure 4-11). One other notable feature of the sandwiched seven strand β-sheet layer 
(order of β-strands 3214657), is that strand 6 is antiparallel to the others. UAM falls under the 
glycosyltransferase family of proteins, which bind a metal co-factor through a DXD-motif and 
catalyze reactions on nucleotide-diphospho sugars. 
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(A)  
(B)  
 
Figure 4-11: Models for OsUAM1, predicted by GalaxyWeb and I-TASSER.59   
(A) OsUAM1 model predicted by GalaxyWeb, highlighting the regions different from the I-tasser 
model in a purple box (B) OsUAM1 model as predicted by I-TASSER, highlighting the regions 
distinct from the GalaxyWeb model in a purple box.  
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In addition to generating a model, I-TASSER was also able to predict the functional 
analogs of the model, by using global and local structural similarity search. In the case of the 
OsUAM model, I-TASSER chose Chondroitin polymerase, a bifunctional glycosyltransferase that 
can bind to UDP-Glucuronic acid (UDP-GlcUA) or UDP-GalNAc and alternatively transfer 
GlcUA or GalNAc moiety to catalyze the elongation of the chondroitin chain.104 Like UAM, 
Chondroitin polymerase also uses Mn2+ as a cofactor and UDP-based substrates and has two 
glycosyltransferase domains. The software also predicts the binding site of UAM by docking UDP-
GalNAc (one of the substrates in the crystal structure of Chondroitin polymerase) in the active site 
of the predicted OsUAM model. This process aids in picking out a few active site residues that 
may bind and interact with the substrate of UAM (UDP-Arap), as shown in Figure 4-12A & B. 
Based on the OsUAM1 model and its comparison with Chondroitin polymerase, the 
following residues predicted by I-TASSER may be able to bind the substrate uridine, sugar, and 
the metal ion cofactor. Residues such as Thr28, Ile29, Asn31, and Asp52 may interact with the 
uridine portion of the substrate (Figure 4-13A) while residues such as Gly242, Arg243, Asp245, 
and Asp246 were predicted to interact with the sugar moiety of the substrate. The most important 
finding regarding this research is the site proposed to bind the metal ion. Residues Asp110, 
Asp111, Asp112, and His273 were predicted to be in the position to bind the metal ion (Figure 4-
12C). The model is in agreement with the hypothesis that, like other members of the 
glycosyltransferase family, UAM uses its metal ion cofactor to bind and stabilize substrate. The 
OsUAM1 model suggests that the above-mentioned residues bind the metal, holding it in place for 
the incoming substrate. As part of this study, SDM was performed on these residues to further our 
understanding of the metal binding site.   
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(A)  
 
(B)  (C)  
 
Figure 4-12: I-TASSER model of OsUAM1 with UDP-GalNAc in its active site and predicted 
uridine, metal and sugar regions of the substrate.60  
(A) I-TASSER model of OsUAM1 with UDP-GalNAc in its active site (B) Predicted regions of I-
TASSER model that can bind uridine (blue), metal (magenta) and sugar (salmon) regions of the 
substrate. (C) Close-up view of predicted metal-binding site of OsUAM1 
 
4.6 Mutation studies on OsUAM1 
 OsUAM1 and OsUAM3 contain a DDD-motif in their sequence (Asp110, Asp111, and 
Asp112 in OsUAM1; Asp108, Asp109, and Asp110 in OsUAM3); in the case of OsUAM2, which 
UDP-
GalNAc 
D110 
D111 
D112 
H273 
Mn
2+
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does not perform the mutase function, the third aspartic acid in the motif is replaced by an 
asparagine (DDN). Mutating Asp112 in OsUAM1 to asparagine (D112N) deleted the mutase 
activity in the enzyme. However, mutating Asn99 in OsUAM2 to an aspartic acid (N99D) alone 
did not succeed in converting OsUAM2 into a mutase.101 As part of this research, four residues 
identified by the OsUAM1 model as having a role in binding the metal cofactor, were mutated to 
alanines so as to analyze their effect on the enzyme activity. From the model, since His273 was in 
close vicinity to the DDD-motif, the possible role of this residue in metal binding was also further 
explored, along with the residues that make up the DDD-motif. 
 
4.6.1 Kinetic study on OsUAM1 wild-type 
The reaction catalyzed by UAM is reversible, with the equilibrium favoring UDP-Arap 
formation. The optimal pH for the formation of UDP-Arap was between 5.5 and 6.0 and that for 
UDP-Araf formation was between pH 7.0 to 7.5.18 The data obtained from our HPLC-based kinetic 
assays were fit to a non-linear regression fit and the kinetic parameters were determined. OsUAM1 
had a Km of 12 ± 1 µΜ for UDP-Araf, and a kcat value of 3.2 ± 0.1 sec-1. The calculated specificity 
constant (kcat/Km) was 0.26 ± 0.1 s
-1µM-1 (Figure 4-13A). 
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(A)  
 (B)  
         (C)      
 
Figure 4-13: Kinetic curves for OsUAM1 wild-type and H273A mutant.61 
Michaelis-Menten Kinetic curve for (A) Wild-type OsUAM1 (B) H273A mutant and (C) Plot of 
% Relative activity vs. Manganese concentration for the H273A mutant.  
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4.6.2 Analysis of OsUAM1 mutants - Role of His273 
OsUAM1 H273A mutant was created by SDM; over-expressed and purified using the same 
procedure described for the wild-type enzyme. Kinetic analysis was performed to see if this 
mutation would have any effect on enzyme activity. In general, the mutant displayed lower activity 
than the wild-type OsUAM1. A Michaelis-Menten curve was obtained by plotting rate against 
substrate (UDP-Araf) concentration. The Km and kcat values, calculated from the Michaelis-Menten 
plot (Figure 4-13B) were 0.76 ± 0.05 µM and 0.05 ± 0.001 sec-1, respectively. The specificity 
constant for this mutant was 0.6 ± 2.0 × 10-2 units. A decrease in both Km and kcat was noted when 
compared to the wild-type enzyme (Table 4-1), which meant that the mutant required less substrate 
to achieve half-maximum activity, but its efficiency was also lower. The metal binding assays 
conducted showed that this mutant followed a similar trend as that of the wild-type enzyme when 
treated with various concentrations of Mn2+. Maximum activity was observed at ~ 80 µM Mn2+ 
and about 80 % or higher activity in the 40 - 200 µM range and a decrease in activity at 
concentrations greater than 320 µM (Figure 4-13C). Since this mutation did not inactivate the 
enzyme, it can be argued that His273 may not be directly involved in coordinating the metal ion. 
 
4.6.3 Analysis of OsUAM1 mutants - Role of DDD-motif 
Like the H273A mutant, three alanine mutants of the OsUAM1 DDD-motif were created 
by SDM and purified adopting the same procedure followed for the wild-type enzyme. The 
purified mutants were concentrated to ~ 1 mg/ml and treated with EDTA to remove any bound 
metal. Kinetic assays were performed with these mutants, using the same procedure followed for 
the wild-type enzyme. All three mutants (OsUAM1 D110A, OsUAM1 D111A, and OsUAM1 
D112A) were inactive when tested without the addition of Mn2+. Moreover, increasing the metal 
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ion concentration to 80 µM (concentration of Mn2+, which gave maximum activity in wild-type 
and H273A mutant) in the reaction mixture, did not improve activity. Furthermore, no conversion 
of the substrate to product observed, when the reaction time was increased (up to 10-fold). Also, 
increasing the mutant enzyme concentration in the reaction by 10-fold did not restore activity in 
these mutants. The complete loss of activity suggests the inability of the DDD-motif alanine 
mutants to bind the Mn2+ cofactor as well as the wild-type enzyme unless the mutations led to 
detrimental changes to the secondary structure of OsUAM1. 
 
Table 4-1: Kinetic parameters of wild-type OsUAM1 and its mutants.12 
 
To ensure that these mutations did not alter the secondary structure of the enzyme, CD 
experiments were performed on the wild-type and all of the OsUAM1 mutants created. The results 
tabulated in Table 4-2, show that all the mutants have comparable % secondary structural elements 
with the wild-type enzyme. These results suggest that mutating the DDD-motif does not drastically 
change the secondary structural elements of OsUAM1, but the activity is quenched since the 
enzyme is probably unable to bind the Mn2+ cofactor. 
 
 
Enzyme Km (µΜ) kcat (s-1) kcat / Km  (s-1µM-1) 
OsUAM1(wild-type) 12 ± 1 3.2 ± 0.1 0.26 ± 0.1 
H273A 0.76 ± 0.05 0.05 ± 0.001 0.6 ± 2.0 × 10-2 
D110A No activity detected 
D111A No activity detected 
D112A No activity detected 
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Table 4-2: Secondary structural elements of wild-type OsUAM1 and its mutants, as 
determined using CD.13 
 
4.7 Discussion  
The metal binding studies performed by Konishi et al. (2007) were limited, as their studies 
gave an incomplete picture of the metal ion dependency of OsUAM. They reported using 5 mM 
final concentration of the metal to perform the reaction. Initial experiments demonstrated that most 
of the enzyme was precipitated (formation of white precipitate in the protein containing tubes) 
with 5 mM of Mn2+. Further, the group also reported that the enzyme was active without the metal, 
as they discovered activity when no metal was added to the reaction mixture.18 Hence, Mn2+ was 
described as an activator of the enzyme. This study claims that Mn2+ is necessary for the activity 
of the enzyme and does not behave as an activator.   
In this thesis, metal binding studies were performed on OsUAM1 and all three AtRGPs. 
All four enzymes, showed maximum activity at lower concentrations, at either 40 µM or 80 µM 
of Mn2+, but their activity decreased when the metal ion concentration was increased higher than 
320 µM. This could be due to the excess metal binding at different sites of the enzyme, interfering 
with bonds between residues and bringing about detrimental changes to the overall structure of the 
Enzyme 
α- helix 
(%) 
Parallel 
β- strands 
(%) 
Antiparallel 
β-strands 
(%) 
β-turns 
(%) 
Random coils 
(%) 
OsUAM1(wild-
type) 
17 13 16 20 48 
H273A 19 14 14 20 45 
D110A 18 15 14 21 46 
D111A 19 14 13 20 45 
D112A 16 16 15 21 48 
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enzyme, thus making it less active. Further, the excess metal could also bind to the charged 
substrate phosphates thereby making them inaccessible to the enzyme.  
The EDTA-treated enzymes were inactive when assayed without metal; however, activity 
was recorded even with metal ion concentration as minimal as 2 µM. This meant that the metal 
ion was necessary for activity rather than it being an activator of the enzyme. Konishi et al. (2007) 
observed only a fractional increase in activity (under 5%) with Zn2+ and Mg2+, compared to the 
activity they obtained with no metal while the others divalent ions did not show appreciable 
activity. Contrary to these observations, our experiments revealed that other divalent metal, such 
as Zn2+ and Co2+, retained at least 60 % of the activity of Mn2+ at the concentration that gave 
maximum activity in all four enzymes. It is also pertinent to note that there was no contaminant 
manganese ions in any of the other divalent metal ion solutions used for the experiment, based on 
the manufacturer’s claim of purity. The high activity of UAM with Mn2+ could be accounted to the 
size of Mn2+, which may be just right to keep UAM’s active site in the right configuration to help 
it coordinate the substrate.  
Despite the importance of the metal cofactor, the information known about the role of the 
metal and its contributions towards the function of the enzyme is minimal, since there is no 
structural information available for this enzyme. Attempts were made to crystallize OsUAM1 and 
AtRGP1, but they were unsuccessful in producing crystals of good quality. Purified OsUAM 
produced a single band at ~ 41 kDa on an SDS-gel, but the molecular weight estimated by size-
exclusion chromatography was ~ 460 kDa.18 OsUAM was likely to exist as a complex made up of 
numerous monomeric units. The oligomeric state of the enzyme could be one of the reasons why 
obtaining diffraction quality single crystals has proven difficult thus far; as larger macromolecules 
generally tend to have more flexible fragments.  
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Nonetheless, an initial sequence-based model was proposed for OsUAM1, which helped 
determine the regions that could form secondary structures and also predicted the possible active 
site residues. The structure models generated from the two different programs, I-TASSER and 
GalaxyWEB, had similar overall architecture and minimal dissimilar regions. I-TASSER predicted 
Chondroitin polymerase as a functional analog of the model of OsUAM1; this enzyme uses Mn2+ 
metal ion cofactor and UDP-based substrates (UDP-GlcUA and UDP-GalNAc). By docking UDP-
GalNAc in the OsUAM1 model, I-TASSER proposed three different loops from the starting model 
that may bind the uridine, diphosphate and sugar regions of the substrate. The model puts the DDD 
motif (the region previously hypothesized to bind the metal cofactor) and His273, in a position to 
bind the metal, which in turn is able to stabilize the substrate.  
To test the role of these residues, alanine mutants of all four residues were prepared and 
tested for activity. All three alanine mutants of the DDD-motif inactivated the enzyme. Histidine 
was not part of the DDD-motif; however, a number of manganese-dependent enzymes have been 
shown to involve their active site histidines for metal coordination. The H273A mutant reduced 
enzyme activity but failed to inactivate the enzyme completely. This could mean that His273 is 
perhaps not directly involved in metal coordination in OsUAM1. Our CD experiments also showed 
that none of the mutants changed the secondary structure of the enzyme, and therefore the loss of 
activity is due to the inability of OsUAM1 to bind the metal cofactor. 
Based on the OsUAM1 model predicted, one of the features of the enzymes that belong to 
the glycosyltransferase family, is the stabilization of the substrate diphosphate by the metal and 
the binding of the metal to the DXD-motif. Like the other proteins in this protein family, in UAM, 
the metal's role could be limited to the phosphate stabilization and may not be involved directly in 
catalysis. In addition, to the work discussed in this chapter, extended X-ray absorption fine 
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structure (EXAFS) was also performed on OsUAM1. The data collection and processing of 
EXAFS data was performed by our collaborators, Dr. Julien Cotelesage, Research Associate with 
Dr. Graham George, Dept. of Geology, University of Saskatchewan. Although the data obtained 
is inconclusive, initial results agree with the above-mentioned role of metal in this enzyme i.e. 
stabilization of substrate diphosphate. Some of the EXAFS results have been included in the 
Supplementary Section S.3. 
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Chapter 5: GDP-6d-altro-Heptopyrnaose Mutase  
GaHM is the first example of a pyranose-furanose mutase enzyme that interconverts a 
heptose sugar. The enzyme has low sequence identity (< 21%) to both prokaryotic and eukaryotic 
UGMs. The sequence alignment shown in Figure 5-1, suggests that GaHM could be a 
flavoenzyme, due to the presence of conserved residues that are known to covalently bind FAD. 
In fact, the purified recombinant CjGaHM enzyme was yellow in colour; the protein fractions had 
the characteristic UV-absorbance at 450 nm indicating the presence of FAD.58 
GaHM catalyzes the interconversion between GDP-altro-Hepf and GDP-6d-D-altro-
heptopyranose (GDP-altro-hepp). According to the studies performed by Dr. Todd Lowary's group 
at University of Alberta, when GDP-6d-D-altro-Hepf was incubated with reduced GaHM, the 
product formed, GDP-6d-D-altro-Hepp was in a 1:1 ratio and the equilibrium did not favor the 
formation of the pyranose form as seen with other previously studied mutases.58  
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Figure 5-1: Sequence alignment of CjGaHM with AfUGM and TcUGM.62 
Conserved residues are shown in red boxes. The residues that interact with FAD are highlighted 
with an *. The sequence alignment was performed using ESPript (Version 3.0) 
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5.1 Structural studies on CjGaHM 
 A low sequence identity meant that homology models of CjGaHM could not be created, 
and hence, X-ray crystallography was used to examine the structure. Recombinant CjGaHM 
enzyme required for crystallization experiments were provided by Dr. Todd Lowary's group. The 
crystal structure of GaHM with GDP was solved by Dr. Sean Darlymple, a former post-doctoral 
fellow in the Sanders lab. The crystal structure of CjGaHM, with FAD, both in oxidized and 
reduced states, was solved initially with GDP in the active site. Since no previous models were 
available for this enzyme and due to its low sequence identity with other UGMs, molecular 
replacement could not be used to solve the structure. Crystals were obtained with Se-Met GaHM 
protein, Figure 5-2 and the structure was solved with single anomalous dispersion (SAD) technique 
using Se-Met for phasing.  
 
Figure 5-2: Crystals of CjGaHM with GDP.63  
These co-crystals were obtained by Dr. Sean Darlymple. 
 
5.1.1 Structural features of CjGaHM 
 The structures of CjGaHM: GDP with FADox and FADred were solved to 2.7 Å and 2.4 Å, 
respectively. GaHM monomer consists of three domains. Domain 1 is the αßα Rossmann fold 
which binds the FAD cofactor, Domain 2 is the α-helical domain containing five α-helices, and 
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Domain 3 is the ß-strand domain, consisting of antiparallel ß-strands, which plays a role in 
interconnecting the two domains, as shown in Figure 5-3. As seen with the structure of UGMs, the 
active site of CjGaHM is located in the cleft below FAD. The overall structural features of GaHM 
compares well with the prokaryotic and eukaryotic UGMs. 
A structural comparison of GaHM with DrUGM (prokaryotic) and AfUGM (eukaryotic) 
UGM crystal structures reveals more details about the enzyme. The structure of CjGaHM is 
comparable to DrUGM (surface area ~ 45600 A°^ 2) but more compact than that of AfUGM 
(surface area ~ 59000 A°^ 2). This is understandable given the length of the sequences of these 
enzymes; the GaHM sequence is longer than that of DrUGM but not as long as that of AfUGM. 
The GaHM crystal structure however is more similar to eukaryotic UGMs. DrUGM, mentioned in 
detail in Chapter 3, has only a single flexible loop that moves into the active site when the substrate 
is present. Eukaryotic AfUGM has two mobile loops that move into the active site if the substrate 
is present in the active site, as shown in Figure 5-3. The structure of CjGaHM also has two mobile 
loops; however, they could not be modeled into the structure due to little or no electron density.  
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Figure 5-3: The crystal structure of CjGaHM: GDP.64  
The three domains, Domain 1 in blue, Domain 2 in green and Domain 3 in grey are shown. The 
start and end of mobile loops 1 and 2 are shown in red. 
 
The objectives of this project were, to understand the structural features of CjGaHM that 
were responsible for substrate recognition and specificity to a GDP-based substrate, instead of the 
usually preferred UDP-based substrate, observed with all UGMs studied thus far. In the CjGaHM 
structure with GDP, there is no electron density available to model the loops. This may be due to 
the absence of the sugar moiety, which helps in additional stabilization of the flexible loop. 
Crystallizing CjGaHM with a GDP-sugar will yield information about the binding of the sugar in 
the active site and the residues that contribute to its stabilization. The substrate GDP-6d-D-altro-
Hepp could not be obtained either commercially or by synthesis. Hence, the crystallization of 
CjGaHM was attempted with GDP-mannose, chosen based on its similarities with GDP-6d-D-
altro-Hepp, as shown in Figure 5-4. 
Domain I:  
FAD-binding 
Domain III:  
-strands 
Domain II:  
-helices 
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Figure 5-4: Difference between GDP-mannose and GDP-6d-D-altro-Hepp structures.65  
GDP-mannose differs from GDP-6d-D-altro-Hepp at C3 and also GDP-6d-D-altro-Hepp has 
seven carbons. 
 
5.2 Crystallization of GaHM with GDP-mannose 
GaHM was co-crystallized with GDP-mannose in the condition containing, 0.1 M 
ammonium sulphate, 0.1 M Bis-tris pH 6.5 and 25% PEG 3350 (Figure 5-5). The diffraction data 
obtained for GaHM: GDP-mannose complex crystals in both FADox and FADred forms were solved 
to 2.1 Å and 2.3 Å resolution, respectively. 
 
 
 
Figure 5-5: Crystals of GaHM: GDP-Mannose.66  
These crystals were obtained in 0.1M ammonium sulphate, 0.1M Bis-tris pH 6.5 and 25% PEG 
3350. 
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5.3 GDP-6d-altro-Heptopyrnaose Mutase structures 
5.3.1 GaHMox: GDP-mannose  
In the crystal structure, GaHM exists as a monomer. There are two monomer units in the 
ASU. The active site of GaHM has residues to bind and interact with the guanosine base of GDP. 
Residues such as Phe147, Pro149, and Tyr146 stack the guanine while Glu98 and Tyr146 make 
strong hydrogen bonding contacts, as shown in Figure 5-6. Glu98 hydrogen bonds to N1 (2.8 Å) 
and the amino group at C2 (2.9 Å) of guanosine. Tyr146 hydrogen bonds (2.7 Å) with N7 of 
guanosine. The guanosine ribose is held in position by a hydrogen bond interaction (2.9 Å) 
between its C2 hydroxyl group and the amino group of Asn151.  
In the sugar binding region, mannose was modeled into the electron density that was 
observed below the FAD. The mannose C1 anomeric carbon is at a distance of ~ 4 Å from the N5 
of FAD. Mannose forms hydrogen bonding interactions with Arg386, Asn394 and His54 residues 
in the active site. The guanidino nitrogens of Arg386 form hydrogen bonds with the C2 and C3 
hydroxyls of mannose at 3.4 Å and 3.3 Å respectively. Hydrogen bonds are also formed between 
Asn394 and the C4 hydroxyl of the sugar and also between His54 and the C6 hydroxyl of mannose. 
In the phosphate binding region, Arg307 is in a position to form contacts with the β-phosphate of 
the substrate.  
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Figure 5-6: A close-up of the active site of GaHM.67  
The residues that bind guanosine (in blue) and ribose of GMP (in green) are shown. The residues 
that make contacts with mannose sugar (in green) are shown in cyan. Arg307, which is in position 
to stabilize the β-phosphate of GDP-mannose is also shown, in magenta.   
 
In the GaHMox: GDP-mannose structure, there is no clear electron density for the two 
flexible loops (Loop 1 residues 164-176 and Loop 2 residues 191-197). Density is observed for 
Loop 2 in chain B, but the loop is in an open conformation, stabilized by interactions with the 
adjacent monomer unit. Moreover, there is no density for the mannose sugar in this chain. In chain 
A, both loops are not visible; they are not in a closed conformation, and the substrate mimic is 
exposed to the solvent, as it is not buried completely within the active site. Despite this, density 
for mannose is observed in this chain.  
Asn151 Phe147 
Pro149 
Tyr146 
Arg307 
Arg386 
His54 
Asn394 
Glu98 
Mannose 
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The problem here is two-fold. Firstly, loop flexibility leads to a loss of information in 
regards to the residues that may bind and stabilize the phosphate. Arg307 is in a position to form 
contacts with the β-phosphate of substrate. This is also observed in the GaHM: GDP complex 
structures solved. However, information regarding the residues which interact with the α-
phosphate and locks down the substrate in the active site is still unavailable. Secondly, the 
flexibility of the loops leads to discontinuous density for the substrate (Figure 5-7A). The 
guanosine monophosphate (GMP) and mannose portions had to be modeled in separately, and 
there is little or no density observed for the β-phosphate. The sugar-binding also becomes flexible 
leading to the observation of two different conformations for the sugar each at on occupancy of 
0.5 (Figure 5-7B). Good electron density for one of these loops (loop 190-197) was observed in 
Chain B of the structure. This was because the loop was stabilized in an open conformation, due 
to crystal contacts, although this caused the absence of electron density for the mannose sugar in 
the active site of Chain B. 
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(A)  
(B)  
Figure 5-7: Electron density maps for GMP and Mannose in GaHMox: GDP-mannose.68  
(A) GMP and mannose sugar modeled in the electron density (1.5 σ) separately due to 
discontinuous density, β-phosphate has no density. (B) The big blob of density surrounding 
mannose in (A) can accommodate two mannose molecules (shown in white, having two 
conformations), illustrating the flexible nature of the mannose binding, due to it being a substrate 
mimic. 
 
GMP 
Sugar 
FAD 
GMP 
Sugar 
FAD 
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5.3.2 GaHMred: GDP-mannose  
The GaHMred: GDP-mannose structure solved to 2.3 Å, shows an overall similar structure 
to the GaHMox: GDP-mannose complex structure as shown in Figure 5-8A. As with the GaHMox 
structure, the electron density for both the loops was missing in monomer A; monomer B had the 
density for Loop 2, but it was in the open conformation. Electron density for GDP-mannose was 
discontinuous in the GaHMred structure, and GMP and mannose were modeled in monomer B 
(Figure 5-8B). Monomer A showed density for GDP but no density under FAD for the sugar. 
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(A)  
(B)  
Figure 5-8: Crystal structure of the overall structures of GaHMred: GDP-mannose.69  
(A) Overall structures of GaHMred: GDP-mannose (in blue) and GaHMox: GDP-mannose (in green) 
(B) The electron density (1.5 σ) and the modeled mannose under the FAD and GMP are shown.  
  
FAD 
GMP Mannose 
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Table 5-1: Data collection and refinement statistics.14 
 GaHMox: GDP-mannose GaHMred: GDP-mannose 
Data collection    
Space group P21 21 21 P21 21 21              
Cell dimensions 47.62, 72.50, 272.89 47.48, 71.65, 272.64 
a, b, c ( Å) 90, 90, 90 90, 90, 90 
Resolution range (Å) 46.9-1.57 (2.10) 46.7-1.87 (2.30) 
All reflections 771658 490592 
Unique reflections 129116 77769 
Redundancy   
I / σI                                                       8.88                                 7.52  
Completeness (%) 95.7 (100)       99.3 (100) 
No. molecules in ASU 2 2 
Data refinement   
Resolution range (Å) 46.9-2.10    47-2.30 
R work / R free 0.1564/0.2049  0.1780/0.2287 
No. amino acid residues  3×418  3×418 
No. of Water (molecules) 606 406 
Ligand   
 FAD  2×FAD 2×FAD 
GMP  2×GMP 2×GMP 
Mannose 1× M1P 1× M1P 
r.m.s deviations   
Bond lengths (Å) 0.008 0.009 
Bond angles (°) 1.096 1.234 
Ramachandran favored 95.7 %  95.9% 
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5.4 Loop modeling  
The electron density for Loop 1 (from Asp163 to Pro178), is not clear or is absent in both 
GaHMox and GaHMred structures. Based on the observations made from the sequence alignment 
with eukaryotic UGMs, (AfUGM and TcUGM), the Loop 1 of CjGaHM is longer by three residues, 
as shown in Figure 5-9. The sequence of Loop 1 in AfUGM and TcUGM have a methionine 
(Met173 and Met171, respectively) and tryptophan (Trp177 and Trp175, respectively) residue that 
is also conserved in GaHM. In all the three sequences, the other end of Loop 1 has proline residues 
that act as starting points to their respective loops. In both AfUGM and TcUGM, a positively 
charged arginine residue (Arg182 and Arg176, respectively) stabilizes the α-phosphate and also 
forms a key hydrogen-bond interaction with asparagine (Asn457 and Asn433, respectively) once 
the substrate is in the active site. In GaHM, the role of arginine is expected to be played by two 
residues, based on the sequence alignment. Lys174, a positively charged residue is expected to 
interact and stabilize the negative charge on α-phosphate.  
 In the case of Loop 2, the electron density is absent from Lys190 to Ala199 in monomer 
B. Loop 2 of GaHM is shorter by a residue, compared to AfUGM and TcUGM sequences. Loop 2 
has five conserved residues in both AfUGM and TcUGM sequences, only one of them; alanine 
(Ala207, Ala205, and Ala199 respectively) is conserved in all three sequences. 
The crystal structures of both AfUGM and TcUGM were used as templates to model the 
missing GaHM loop regions, due to the similarities in sequences and the crystal structures 
themselves.34,36 GaHM residues Met162 through Trp166 were modeled, corresponding to the 
position of the above-mentioned conserved methionine and tryptophan residues, in Loop 1 of 
AfUGM and TcUGM. The other end of the loop, from Pro178 to Lys174, was also modeled based 
on the similarities with residues from the eukaryotic UGM sequences, in such a way that Lys174 
143 
 
is in a similar position to that of the Arginines in AfUGM and TcUGM.34,36 The eukaryotic UGMs 
have a small helix (α-15) located in front of the cleft and isoalloxazine ring of FAD, as shown in 
Figure 5-9. The helix functions to ensure that the substrate is completely buried in the active site 
of the eukaryotic UGMs. This small helix is completely absent in GaHM. Therefore the remainder 
of Loop 1, between residues Ile167 to Met173, was modeled in a position similar to that occupied 
by this helix.  
 
Figure 5-9: Overlay of crystal structures of AfUGM and CjGaHM.70  
Loop1 and Loop2 of CjGaHM (shown in green), modeled on Loop1 and Loop2 of AfUGM (shown 
in orange). The region of CjGaHM Loop1 (residues Ile167 to Met173) modeled in the region 
occupied by the short helix of AfUGM (magenta) is highlighted in magenta.  
 
 
Loop2 
Helix α-15 
Loop1 
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The role of Loop 2 is to help bury the substrate completely in the active site of the enzyme 
by moving in towards the active site in the presence of substrate, to contribute residues such as 
Asn207 in AfUGM and Asn200 in TcUGM, which can interact with the hydroxyls of the sugar.34,36 
Despite the dissimilarity of the sequences, Loop 2 of GaHM was also modeled similar to the loops 
from AfUGM and TcUGM.  
 
5.5 Discussion 
5.5.1 Specificity for GDP-based substrate 
 To understand the specificity of CjGaHM to a GDP-based substrate, the residues around 
the GDP-binding site were compared to those from eukaryotic UGMs, since the overall crystal 
structures were similar. The sequence alignment showed that the residues corresponding to these 
regions are similar, with a few exceptions. All three sequences have conserved tryptophan, valine, 
tyrosine, proline and isoleucine residues. However, it is the substitution of Phe105 in both 
eukaryotic UGMs with a less bulky non-aromatic Ile97 in GaHM and a further substitution of the 
basic glutamine residue (Gln106) in eukaryotic UGMs by an acidic glutamate (Glu98) in GaHM, 
which helps GaHM recognize and bind a GDP-based substrate. Glu106 is able to make two 
hydrogen bonds with the uracil ring while Gln98 has the ability to make two hydrogen bonds with 
guanosine, as shown in Figure 5-10. Thus, these subtle changes in the active site aid the binding 
of a GDP-based substrate by GaHM. 
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(A)  
(B)  
Figure 5-10: Overlay of the nucleotide-binding region of AfUGM and CjGaHM.71  
(A) Glutamic acid is in position to interact with the guanosine in CjGaHM (green) (B) Glutamine 
interacts with uridine in AfUGM (orange). 
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5.5.2 Stabilization of the α-phosphate 
In the crystal structures of CjGaHM, solved with GDP-mannose, the flexible mobile loops 
that close to bury the substrate in the active site could not be built-in, due to little or no electron 
density. The overall structural similarity of CjGaHM, with structure of eukaryotic UGMs such as 
AfUGM and TcUGM, enabled the modeling of the flexible loops of CjGaHM,  
To identify other residues of the CjGaHM active site that interact with the substrate, the 
residues contributed by the loop regions of the enzyme were compared to eukaryotic UGMs. The 
mobile loop brings in an arginine residue (Arg180 in AfUGM and Arg176 in TcUGM) which 
stabilizes the α-phosphate. This residue also interacts with an Asn (Asn457 in AfUGM and Asn453 
in TcUGM), to keep the enzyme in a closed conformation. In fact, this is also seen in prokaryotic 
UGMs, as discussed in Chapter 3. Based on the modeled Loop 1, the role of arginine is performed 
by two residues in CjGaHM. Lys174 moves in with the loop to stabilize the α-phosphate. However 
since lysine lacks the guanidino group of arginine, it cannot form hydrogen bond interactions with 
Asn394. The sequence alignment suggests that one of the residues that follows, such as Gln172 
should be able to play such a role. The loop may thus be kept in a closed conformation by Gln172, 
which forms hydrogen bonds with Asn394 of CjGaHM as shown in Figure 5-11. 
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Figure 5-11: Active site residues of CjGaHM predicted to keep Loop 1 in a closed 
configuration.72  
The CjGaHM are shown in green. Lys174 stabilizes the α-phosphate while Gln174 forms hydrogen 
bonds with Asn394 to keep the loop closed and bury the substrate. Arg182 which interacts with 
Asn457 in AfUGM to maintain the loop in a closed configuration is also shown in orange.  
GMP 
FAD 
Mannose 
Arg182 
Asn394 
Asn457 
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148 
 
Chapter 6: Conclusions and future work 
 Furanoses are vital components in the cell wall of bacteria, fungi, plants and protozoa. It is 
important to study the furanose containing glycoconjugates since they are absent in humans and 
mammals. Their identification in disease-causing pathogens means the enzymes aiding in the 
production of furanoses are potential drug targets. In this thesis, three different pyranose-furanose 
mutases (UGM, UAM, and GaHM), employed by their respective pathways leading to the 
deposition of three different furanoses in the cell wall of various organisms, were studied. 
 From literature, the understanding of these mutases is to varying degrees. In this thesis, the 
objectives were outlined so as to focus on the substrate-binding aspects of these mutases. Two of 
these enzymes, UGM and GaHM, require the same cofactor (FAD) for their respective 
interconversion reaction, but bind UDP and GDP based substrates, respectively. Also GaHM, 
unlike any of the mutases described so far, catalyzes the interconversion of a heptose-sugar. Plant-
enzyme UAM is a metalloenzyme that does not require FAD for activity but works on a UDP-
based substrate. Therefore, the requirement for different substrates and different cofactors meant 
that the modes of substrate binding were different among the three enzymes. 
 
6.1 UGM 
DrUGM was chosen as a model system to study how substrate binding is affected by the 
active site residues of the enzyme. The importance of only a few residues in binding the substrate 
in the most productive conformation is known in UGM. Changes were introduced to the active site 
in the form of point mutations, and experiments were designed to understand the role of these 
residues. Kinetic assays, modeling, and docking studies were performed on DrUGM mutants. The 
studies have established the roles of Trp184, Arg364, His88 and Asn372 and residues performing 
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similar roles in the active sites of other UGMs. Trp184, an important residue required to position 
the uridine-portion of the substrate, not only makes contacts with the uridine-ribose but also helps 
stack it in the active site, thereby increasing the efficiency of the enzyme. Arg364 and Asn372 
keep critical residues like Arg198 in the correct position. His88 positions the sugar (Galp) under 
FAD for catalysis. All of these residues contribute to enabling the substrate to bind in the most 
productive mode in the active site. Minor changes in the active site conformation affected the 
substrate binding mode of this enzyme and which tends to place the sugar (Galp) further away 
from the N5 of reduced FAD, thereby causing depletion of activity. 
MtUGM is a validated drug target. The inhibitor MS-208 binds to an allosteric site on the 
enzyme and causes changes to the substrate binding mode, altering the positioning of Arg182 
(residue contributed by the mobile loop). MS-208 was tested against MtUGM and the data obtained 
was globally fit to the equation for mixed-type inhibition. The Ki and Ki' of the inhibitor calculated 
from the fit were ~135 µM and ~400 µM respectively. Though evidence for the exact conformation 
of the binding of MS-208 to the allosteric site is yet to be found, the studies have shown the 
importance of having the active site residues of UGM in the correct conformation so that the 
substrate binds in the productive mode. 
 
6.2 UAM 
Chapter 4 of the thesis discussed the results obtained from the plant metalloenzyme UAM. 
Konishi et al., (2007), who identified this enzyme in O. sativa, described Mn2+ as an activator of 
UAM at 5 mM concentration. Our results from HPLC assays showed that Mn2+ is essential for 
UAM activity, and 5 mM concentration of Mn2+ had an inhibitory effect on UAM activity. This 
was also observed with all three AtRGPs. All four enzymes showed maximum activity at 40-80 
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μM Mn2+ range. Among the other divalent metal ions tested, Zn2+ and Co2+ showed 60-70 % 
activity at this concentration.   
More studies were focused around the metal cofactor and its interaction with the substrate. 
A starting model for UAM was developed based on the OsUAM1 sequence, using I-TASSER and 
GalaxyWEB. On comparison with a functional analog, I-TASSER predicted few possible active 
site residues that can interact with different regions of the substrate. Asp110, Asp111, Asp112 
(DDD-motif) and His273 are in position to bind the metal in OsUAM1. The prediction was tested 
by mutation of the residues mentioned above to alanines. None of the mutations influenced 
changes in the secondary structure, yet the DDD-motif mutants lost activity, indicating the inability 
of the enzyme to bind its metal cofactor. SCOP classification of the OsUAM1 model also suggests 
that role of the metal cofactor is to coordinate and stabilize the substrate diphosphate. EXAFS 
studies were performed on OsUAM1 samples and a preliminary model for the metal binding region 
in OsUAM1 was proposed, by our collaborators. The EXAFS data is in agreement with the 
observations made from the I-TASSER model.  
 
6.3 GaHM 
The thesis also discusses results from work on a third pyranose-furanose mutase, CjGaHM. 
Our crystal structures show that the active site, though similar to UGMs, can adapt to bind and 
interact with the guanosine of GDP-based substrates. The GaHM domains that bind FAD and 
substrate are overall similar to eukaryotic UGMs. Crystal structures of GaHM (FADox and FADred) 
were obtained with the substrate mimic, GDP-mannose. The structures show no electron density 
for two large flexible loops. This is due to the loops being unable to form enough contacts with 
GDP-mannose to exist in a closed conformation so as to bury the substrate completely in the active 
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site. As a result, the sugar and ß-phosphate of GDP-mannose remain flexible in the active site and 
are unable to form stable interactions with active site residues. This limits the information on active 
site residues that can stabilize the phosphate and bind the sugar of substrate mimic, GDP-mannose. 
The loops were modeled into the GaHM crystal structure based on the eukaryotic UGMs, 
and the GaHM residues that may interact with the substrate diphosphate and the sugar were 
identified. The role of the arginine residue that stabilizes the α-phosphate and keeps the loop in a 
closed conformation, in all the known UGM structures thus far, may be accomplished by two 
residues Lys174 and Gln172 in CjGaHM. However this is only a predicted model for the closed 
conformation of the loops and only a crystal structure of the enzyme with its substrate, GDP-6d-
altroHepp, can provide further evidence. 
 
6.4 Future directions 
All three mutases perform similar reactions and yet they are each unique in their own way. 
Once the substrate is recognized, the active sites of these enzymes prepare to bind the substrate in 
a productive binding mode for catalysis to occur. This is best exemplified by UGM. Though the 
sequence identity is very low, these mutases can adapt their active sites to bind their respective 
substrates and cofactors. Some directions for further studying these enzymes are suggested. 
 
6.4.1 Studies on the allosteric site of MtUGM 
The model proposed by the Pinto group (Simon Fraser University, British Columbia) for 
MS-208 binding to the allosteric site suggests that the inhibitor interacts with hydrophobic residues 
such as Pro246, Trp260, Ala320 and Pro326 of the allosteric site (Figure 6-1). The backbone 
carbonyl oxygen of Glu321 forms hydrogen bonds with the hydroxyl group of MS-208. To study 
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how they affect the binding of MS-208 with the enzyme, alanine mutants of these allosteric site 
residues can be created and evaluated kinetically with and without MS-208. This study will help 
gain some insight into the location of the allosteric site, as a complete loss in MS-208 inhibition 
for an alanine mutant of a residue in the allosteric site may provide an indirect evidence for the 
location of this site. 
 
Figure 6-1: The proposed binding site of MS-208 in MtUGM.73  
MS-208 is depicted as a green stick model. The hydrophobic, positively charged and negatively 
charged residues around the site are shown in magenta, yellow and green lines respectively. 
 
Since this is the first instance of identification of an allosteric site on UGM, obtaining a 
crystal structure of MtUGM with the inhibitor MS-208, will not only confirm the presence of the 
allosteric site but will also indicate how the inhibitor interacts with the enzyme and the changes 
undergone by the enzyme’s active site due to binding of the inhibitor. However, MS-208 is poorly 
soluble in water, ruling out preparing solutions of high concentrations, a requisite for performing 
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co-crystallization experiments. More soluble versions of MS-208 can be synthesized and used for 
crystallization trials, to obtain crystals of MtUGM, complexed with substrate in the active site and 
the inhibitor at the allosteric site. This will not only confirm the identification of an allosteric site 
but will also provide indications of whether more than one molecule of MS-208 can bind MtUGM. 
Active site residues have been studied as part of this research to understand their role in 
substrate binding. The active site of UGM is incomplete unless the mobile loop closes around the 
substrate, as evidenced by the UDP-Galp bound structures of this enzyme. This closure helps 
position and orients the substrate in a productive conformation within the active site. In the 
substrate bound crystal structure of MtUGM, Trp166 and Arg261 have been hypothesized as 
residues which control the closure of the mobile loop. In the open loop conformation, Trp166 and 
Arg261 form a cation-π interaction, which is broken due to a 180° rotation of Arg261, to let the 
substrate enter the active site. Hence, to test the hypothesis mutational and kinetic analysis of these 
critical residues need to be performed.  
 
6.4.2 Crystallization and EXAFS on UAM  
 Determining the crystal structures of OsUAM1 and/or AtRGPs will in fact be the first 
reported structures of plant UAM. This will give significant inputs into the mechanism of UAM 
and how its catalytic mechanism compares to that of UGM. If crystallizing these enzymes still 
remains tedious, more EXAFS studies can be performed on all four enzymes, to compare and 
contrast their metal-binding region and ascertain the sugar (Arap) binding residues. 
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6.4.3 GaHM 
 Crystallizing CjGaHM with its substrate GDP-6d-altroHepp may stabilize its flexible 
loops, leading to further understanding of the substrate binding mode of this enzyme and how it 
compares to other known UGMs.   
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Supplementary Notes 
S.1 Modeling of DrUGM mutants using Rosetta-Backrub 
DrUGM mutants were modeled using an online software Rosetta-Backrub.86,88 This 
software calculates the best orientation of the mutant residues by taking into account the flexibility 
of the residues around the point mutation and modeling the backbone chains when the mutant 
models are generated. The backbone chains are modeled by the "Backrub" step, which picks two 
amino acids along a chain length of 2-12 residues apart and rotates it along an axis drawn along 
the Cα of the residues. At the start, the program decides if it can pick only a single residue (residue-
only) or select a backbone (backbone move), based on a probability (Protamer) score. The default 
score for choosing a rotamer-only move is 0.25. If this is chosen, the program just picks up the 
single residue and applies random rotamers to the residue, based on a backbone-dependant rotamer 
library. This library is based on crystallographic structures that have already been solved. If the 
rotamer-only move is not selected, then a segment of the backbone is chosen, and rotation is 
performed. The backbone rotation is performed using the backrub step and is called as the 
backbone only move. Next, the algorithm decides if it can stop based on the second adjustable 
probability, Pbackbone. To make the selection of this move more frequent, the default score for 
Pbackbone is set at 0.75. One or a couple of the residues are selected along the chosen backbone 
segment, and random rotamers are applied. Rosetta full-atom scoring function and Metropolis 
criterion are then used to evaluate the move. Backrub moves are applied to any heavy atoms within 
the range of 6 A° around the desired point mutation. A flowchart describing the procedure adopted 
is shown in Figure S-1. 
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Figure S-1: Flowchart describing the method adopted by Rosetta-Backrub software.74 
 
All the requisite information, such as starting angles and backbone parameters, are obtained 
from the input structure file provided in the Protein Data Bank (PDB) format. Ligands are not 
included for performing these simulations. Rosetta Backrub can be accessed online at: 
https://kortemmelab.ucsf.edu/backrub/cgi-bin/rosettaweb.py?query=index. 
 
S.2 GOLD docking for DrUGM mutants 
Docking of the substrate (UDP-Galp) into the active site of the DrUGM mutants was 
performed using the GOLD software (version 5.2.2).89-92 One of the features of the software, 
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'Ensemble docking' was used to get a direct comparison and analysis of the results from the wild-
type and mutant enzymes. At first, an ensemble of proteins was created by superimposing the 
structures considered for the docking experiment, and the substrate was then docked into the active 
site of the ensemble created. Typically, the crystal structure of the wild-type enzyme was 
superimposed on the modeled structure of mutants considered for the experiment. UDP-Galp was 
then docked back into the active site of the ensemble, so that it can now simultaneously get docked 
in the active site of all the protein structures, in a single run. This method is advantageous as it 
generates numbers that can give a direct comparison of which protein binds the substrate better 
and generates docking poses for each of the protein in the ensemble.  
 
S.3 EXAFS on OsUAM1  
S.3.1 Sample preparation 
 For EXAFS experiments, the histidine tag was removed. TEV protease was added to the 
purified OsUAM1 with the 6xhistidine tag and left to react overnight at 4 °C. The sample was then 
loaded onto a Protino column previously equilibrated with 25 mM Bicine pH 8.5. OsUAM1 
without the His-tag was collected in the flow through. The fractions were concentrated to ~ 25 
mg/ml in 25 mM Bicine pH 8.5. Two samples were prepared for the EXAFS study. To gain insights 
about the residues involved in the binding of the metal cofactor, OsUAM1 samples were prepared 
with 0.5 mM MnCl2. To understand the change in metal coordination after addition of substrate, 
UDP-Arap was added to OsUAM1 samples with Mn2+. 30% glycerol was added to all samples 
before freezing, decreasing the protein concentration to ~ 17 mg/ml.  
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S.3.2 Results 
Since UAM is a metalloenzyme, metal absorption edge EXAFS was used to improve 
accuracy and supplement the metal binding site prediction made by the I-TASSER model. EXAFS 
was used to map the active site residues coordinating the metal and predict how the substrate 
interacts with the metal. A change in spectra in the presence of substrate binding is indicative of 
changes around the metal when the substrate enters the active site. Additionally, EXAFS was used 
to determine the distances between the metal and the neighboring atoms.105 Data obtained for two 
different samples of OsUAM1, UAM-Mn
2+
 and UAM-Mn
2+
-UDP-Arap, were cut off at a k range 
of 12. Some important differences in EXAFS spectra obtained with and without substrate were 
observed at ~2.1 Å, ~2.5 Å and 3.4 - 3.6 Å away from the metal, as shown in Figure S-2A. These 
differences in the EXFAS spectra are due to the metal making new interactions with the incoming 
substrate. Theoretical models were designed and fit to UAM-Mn2+-UDP-Arap EXAFS data that 
was obtained using FEFF, a software used to fit experimental spectra to theoretical calculations. 
A few theoretical models with different combinations of the DDD motif, metal, diphosphate and 
water were made, and EXAFS data for all of them were simulated using FEFF and fit to the original 
EXAFS data obtained. A model that agrees reasonably well with the original EXAFS data is shown 
in Figure S-2B and C. This model, with residues Asp110, Asp112, the di-phosphate of substrate 
and two water molecules, accounts for most of the peaks in the experimental data, as shown in 
Figure S-2B. The metal, Mn2+ makes an octahedral coordination. The peak at ~ 2.2 Å is due to six 
separate contributions; one each from carboxyl oxygens of Asp110 and Asp112 residues, one from 
each phosphate oxygen of the substrate and two adjacent water molecules. The peak at 3.4 - 3.6 Å 
can be explained by the distance between phosphorous atoms of the substrate and Mn2+. Further 
experimental data is required to improve this theoretical model further.            
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(C)  
Figure S-2: EXAFS studies on OsUAM1.75  
(A) EXAFS data for UAM with Mn
2+ (trace in black)
 
and UAM-Mn
2+
-UDP-Arap (trace in red) 
(B) EXAFS data for UAM-Mn
2+
-UDP-Arap (trace in black) overlapped on the FEFF spectra 
produced from the model (trace in red) (C) Model designed with two aminoacid residues (D110 
and D112), both in green; water molecules in red, Mn2+ in purple and the substrate diphosphate in 
orange. 
 
S.4 OsUAM1 Modeling 
GalaxyWEB and I-TASSER were used to generate 3D-models of OsUAM1.87,88 I-
TASSER server predicts the 3D-structure and function of a protein of interest based on multiple 
threading alignments and structural simulations. The threading procedure is performed by the 
locally installed meta-threading-server (LOMETS), having individual alignment and scoring 
programs, which compares regions of the input sequence to structures found in PDB. Regions of 
the input sequence, for which templates are found, are incorporated into different structural 
assemblies and the regions of the sequence that do not have a template, mostly loops, are built in 
by modeling. Restraints from LOMETS, based on the PDB structure-templates chosen to run 
simulations at different temperatures, are incorporated into the structural assemblies. The various 
structural assemblies are clustered, and cluster centroids are picked for the next stage, which 
Diphosphate  
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D110 
D112 
Mn
2+
 
H
2
O 
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focuses on removing steric clashes and refinement of global topology. This is established by 
incorporating only the restraints from LOMETS to the PDB structures closest to the clusters 
chosen. Another simulation is performed for hydrogen-bond optimization so that only the lowest 
energy structures produce the final models. The function of the protein of interest is also 
determined by matching the final predicted models with structures from PDB having known 
functions. I-TASSER can be accessed online at: http://zhanglab.ccmb.med.umich.edu/I-
TASSER/.  
GalaxyWEB predicts the protein structure of a given sequence using multiple template-
based modeling (GalaxyTBM) and refines unreliable loop regions by optimization-based 
refinement (GalaxyREFINE). The software has four different stages such as template selection, 
sequence alignment, model building and refinement. The multiple template selection and scoring 
are performed by HHsearch. The matching regions are chosen as templates and the regions of the 
input sequence that do not have templates are built in. Initial model structures are built using 
restraints obtained based on templates and multiple sequence alignments. The unreliable loop 
regions, defined as URLs are then built using loop-closure algorithms. GalaxyREFINE is used for 
further refinement of the predicted models. GalaxyWEB can be accessed online at: 
http://galaxy.seoklab.org/.   
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